December 7, 2016

CURRICULUM VITAEHal Scofield, M.D.

Personal Data

Date of birth: March 8, 1958Birth Place: Lewisville, TexasMarital Status: Married, Bea ScofieldChildren: 3, Nicole, Stuart, AmandaAddress: Home 732 NE 18th Street

Oklahoma City, OK 73105(405) 528-4963

Office Arthritis and Immunology ProgramOklahoma Medical Research Foundation825 NE 13th StreetOklahoma City, OK 73104office phone - (405) 271-7061lab phone - (405) 271-7394Fax - (405) 271-4110

E mail hal-scofield@omrf.ouhsc.edu

Education

1980 B.A. Chemistry, Texas A&M University, College Station, TX

1984 M.D. University of Texas Southwestern Medical School, Dallas, TX

Postgraduate Training

1989-1991 Associate Research Scientist, Arthritis and Immunology Program,Oklahoma Medical Research Foundation, Oklahoma City, OK

1988-1991 Fellow, Section of Endocrinology, Metabolism and Hypertension,Department of Medicine, University of Oklahoma Health Science Center,Oklahoma City, OK

1987-1988 Chief Medical Resident, Department of Medicine, University ofOklahoma Health Science Center, Oklahoma City, OK

1984-1987 Resident in Internal Medicine, Department of Medicine, University of

1

Oklahoma Health Science Center, Oklahoma City, OK

Professional Experience

2003-present Professor, Section of Endocrinology, Department of Medicine, Universityof Oklahoma Health Science Center, Oklahoma City, OK

1997-present Adjunct Associate Professor, Department of Pathology, University ofOklahoma Health Science Center, Oklahoma City, OK

2011-present Member, Arthritis and Immunology Program, Oklahoma MedicalResearch Foundation, Oklahoma City, OK

5/08-6/2011 Associate Dean for Clinical & Translational Research, College ofMedicine, University of Oklahoma Health Sciences Center

1997-2003 Associate Professor, Section of Endocrinology, Department of Medicine,University of Oklahoma Health Science Center, Oklahoma City, OK

1999-2002 Investigator, WK Warren Medical Research Institute

1/98-7/98 Visiting Scientist, Centro de Biología Molecular 'Severo Ochoa' (TheSevero Ochoa Center for Molecular Biology), Univerisidad Autónoma deMadrid, Facultidad Ciencia Biologia, Madrid, Spain (In the laboratory ofJosé Antonio López de Castro)

1992-1997 Adjunct Assistant Professor, Department of Pathology, University ofOklahoma Health Science Center, Oklahoma City, OK

1991-1997 Assistant Professor, Section of Endocrinology, Department of Medicine,University of Oklahoma Health Science Center, Oklahoma City, OK

1993-2011 Associate Member, Arthritis and Immunology Program, OklahomaMedical Research Foundation, Oklahoma City, OK

1991-1993 Assistant Member, Arthritis and Immunology Program, OklahomaMedical Research Foundation, Oklahoma City, OK

1/91- 6/91 Instructor, Section of Endocrinology, Department of Medicine, Universityof Oklahoma Health Science Center, Oklahoma City, OK

2

Board Certification

1988 Diplomate of the American Board of Internal Medicine (permanent certificationand maintaining certification through AIBM)

1991 Diplomate of the American Board of Internal Medicine, Endocrinology,Diabetes, and Metabolism Subspecialty (expired 2001)

2001 Re-certified, American Board of Internal Medicine, Endocrinology,Diabetes, and Metabolism Subspecialty (maintaining certification through ABIM)

2014 Re-certified, American Board of Internal Medicine, Endocrinology,Diabetes, and Metabolism Subspecialty (maintaining certification through ABIM)

Awards

Distinguished Student, Texas A&M UniversityStewart Wolf Award, 1987, Outstanding Medicine ResidentW.W. Rucks Fellowship, 1988-1989Presbyterian Health Foundation Fellowship, 1989-1991Visiting Professors Award, Outstanding Paper, OUHSC Housestaff

Scientific Session, 1989Best Paper in Internal Medicine, OUHSC Housestaff Scientific

Session, 1990Lloyd Radar Scholarship, Outstanding Postgraduate Trainee OUHSC, 1990Physician Scientist Award, National Institutes of Health,

Institute of Musculoskeletal and Skin Diseases, 1992-1997Merrick Award, Oklahoma Medical Research Foundation, 1992Internal Medicine Faculty Teaching Award, Department of Medicine, OUHSC, 1995OUHSC Provost Award for research by an Assistant Professor, 1996Henry Christian Award (for most outstanding abstract in rheumatology, allergy and

immunology), American Federation of Medical Research, 1997 national meetingFellow, American College of Physicians, 1998James A. Shannon Director’s Award (NIAMS and the Office for Research on Women’s

Diseases), 2001OUHSC Provost Award for research by a senior faculty member, April 29, 2002Oklahoma Health Research Committee, 2003-present (appointed by Governor Brad

Henry)Ethel Baxter Award for Outstanding Sjögren’s Syndrome Abstract, American College of

Rheumatology National Meeting, 2004Federation of Clinical Immunology Societies (FOCIS) Travel Award, 2006 national

meeting

3

University of Oklahoma Board of Regents Award for Superior Creative Activity, 2014 Cecil Martin Distinguished Lecturer, Southern Illinois College of Medicine, 2016Lewisville High School Hall of Fame inductee, 2016

Memberships

American College of PhysiciansAmerican College of RheumatologyAmerican Federation of Clinical ResearchThe Endocrine SocietyAmerican Association for the Advancement of ScienceAmerican Diabetes AssociationOklahoma Rheumatism AssociationThe Society of General Internal MedicineThe New York Academy of SciencesAmerican Association of ImmunologistsApplied Research Ethics National AssociationClinical Immunology SocietySouthern Society for Clinical Investigation

Institutional Duties

Pharmacy and Therapeutics Committee, Veterans Administration Medical Center,Oklahoma City, OK, 1987-1988

Environmental Committee, Veterans Administration Medical Center, Oklahoma City,OK, 1987-1988

Ambulatory and Emergency Care Committee, Oklahoma Memorial Hospital, Universityof Oklahoma Health Science Center, Oklahoma City, OK, 1987-1988

Clinical Competence Committee, Internal Medicine Residency Program, University ofOklahoma Health Science Center, Oklahoma City, OK, 1987-1988, 1991-present

Ad Hoc Intern and Residence Day Committee, Department of Medicine, 1991Housestaff Recruitment Committee, Department of Medicine, University of Oklahoma

Health Science Center, 1991-1992, 1992-1993, 1993-1994, 1994-1995.Coordinator, Combined Adult, Pediatric and Gynecologic Endocrine Seminar, 1991-1995Medical Records Committee, Oklahoma Memorial Hospital/University Hospital/

OU Medical Center, 1992-present, Chairman, 1998-presentUniversity of Oklahoma Health Sciences Center Representative to the American

Federation of Clinical Research, 1992-2000Coordinator, Department of Medicine Research Seminar, 1992-1998Member, Institutional Review Board (formally the Human Investigation Committee),

Oklahoma Medical Research Foundation, 1992-presentMember, Research and Development Committee, Department of Veterans Affairs

4

Medical Center, Oklahoma City, OK, 1993-2001; Vice-Chairman, 1995-1998,Chairman, 1998-2001, 2009-1012

Member, Medical Residency Education Review Committee, Department of Medicine,University of Oklahoma Health Science Center

Chairman, Institutional Review Board (formally the Human Investigation Committee),Oklahoma Medical Research Foundation, 1995-2003

Member, Research Committee, Department of Medicine, University of Oklahoma HealthScience Center, 1996-99

Member, Patient Care Committee, The University Hospital/OU Medical Center,University of Oklahoma Health Sciences Center, 1997-present

Member, Research Council, University of Oklahoma Health Science Center, 2003-2006Director, Endocrinology, Metabolism and Hypertension Fellowship,1 July 2005 - presentMember, Department of Veterans Affairs Medical Center IUCAC, 2012-present Co-Director, History of Medicine Enrichment Course, College of Medicine, OUHSC,

2011-present

Community Service

Volunteer physician, Variety Clinic, Oklahoma City, OK, 1985-1988.Volunteer physician, Salvation Army, 1988-1990.Volunteer physician, American Diabetes Association Oklahoma Chapter Summer Camp,

1990, 1991, 1992, 1993, 1994, 1995, 2000, 2001, 2002, 2003, 2004, 2005.Member, Camp Committee, American Diabetes Association Oklahoma City Affiliate,

1992, 1993, 1994, 1995.Volunteer physician, Little Flower Clinica, 1992-2005.Medical Director, American Diabetes Association Oklahoma City Affiliate Day Camp,

1994, 1995Board of Directors, Lincoln Terrace Neighborhood Association, 1994-1996Member, Citizens Advisory Committee to the Capital-Medical Center Zoning

Commission, 1994-1998Member, Admissions Committee, Oklahoma School of Science and Mathematics, 1996,

1997, 2000-presentScience Fair Judge, Classen School for Advanced Study, Oklahoma City School District,

1998-2009Medical Director, Camp Endres (Oklahoma camp for children with type 1 diabetes) at

Camp Classen, Davis, OK, 2007-present

Professional Service

Abstract Reviewer, Midwest Section of American Federation of Clinical Research andCentral Society for Clinical Research Scientific Meeting, 1993, Rheumatology,Immunology and Allergy

5

Member, American Diabetes Association National Research Grant Review Panel, 1993-1996

Member, Humoral Aspects of Autoimmune Disease Abstract Selection Committee,American College of Rheumatology Annual Meeting, 1994

Member, Spondyloarthropathies Abstract Selection Committee, American College ofRheumatology Annual Meeting, 1994

President, Oklahoma Rheumatism Association, 1994-1995Councilor, Midwest Region, American Federation of Clinical Research, 1995-1998Member, Planning Committee, National Human Subjects Protections Workshop -

Cultural Diversity and Other Human Research Issues with Emphasis on NativeAmericans (sponsored by The Office of Protection from Research Risks, Office ofExtramural Research, National Institutes of Health), May 1996

Scientific Program Director, Oklahoma Rheumatism Association Ishmail Lectureship,1997

Program Director, Oklahoma Chapter of the American College of Physicians andOklahoma Society of Internal Medicine Annual Meeting, November 1997

Member, Spondyloarthropathies and Infectious Arthritis Abstract Selection Committee,American College of Rheumatology Annual Meeting, 1997

Member and Reviewer, National Associates Competition Review Board, AmericanCollege of Physicians National Meeting, 1999, 2000, 2001, 2002, 2003

Member, Planning Committee for Experimental Biology 2000, American Federation forMedical Research, 1998-1999

Member, Spondyloarthropathy Abstract Selection Committee, American College ofRheumatology annual meeting, 1999

Member, Medical & Scientific Advisory Board, Spondylitis Association of America,1999-2003

Chairman, Spondyloarthropathy Abstract Selection Committee, American College ofRheumatology annual meeting, 2000, 2001, 2002, 2003

Member, Planning Committee, American College of Rheumatology annual meeting,2000, 2001, 2002, 2003

Ad hoc grant reviewer, March of Dimes, 2003Member, Advisory Board, Abbott Scholar Award in Rheumatology Research, 2002Member, American College of Rheumatology Research and Education Fund national

grant review committee D, Sept 2005, 2006 Councilor, Southern Society for Clinical Investigation, 2006-2009.Member, American Association for the Advancement of Science/Simmons Foundation

grant review committee, December 1, 2008Abstract Reviewer, Head, Rheumatology, Allergy, Immunology, Southern Society for

Clinical Investigation, February 2009 meetingAbstract Reviewer, Head, Adult Case Reports, Southern Society for Clinical

Investigation, February 2009 meetingGrant Reviewer, Target Identification in Lupus, Alliance for Lupus Research, 2008, 2009,

2010, 2011

6

Member, Sjögren’s Syndrome Practice Guidelines Development Committee, Sjögren’sSyndrome Foundation, October 2009-present

Abstract Reviewer, Spondyloarthropathy Abstract Selection Committee, AmericanCollege of Rheumatology annual meeting 2010

Member, Lupus Research Institute, Novel Research Task Force, September 19. 2011 Member, Target Identification in Lupus Grant Review, Panel, November 2011Member, Executive Committee, EULAR and ACR Joint Committee on Classification of

Sjögren’s Syndrome NIH/VA Study Section Duties

Member, General Medicine A subcommittee (GMA-1) - 12/6/2000, 10/22/2001,2/27/2002, 6/17/2002, 10/07/2002, 2/25/2003, 6/16/2003

Member, Arthritis, Connective Tissue and Skin (ACTS) - 10/20/2003, 2/23/2004,6/14/2004, 10/5/2004, 2/15/2005

Member, NIAMS Special Emphasis Grant Review Committee (ZAR1 GHN-DM2 1), Career Development RFA, February 13, 2004.

Member, ZAR1 BHD-B (M2), NIAMS Special Emphasis Panel - 5/5/1999Member, ZAR1 AAA-C (O1), NIAMS Special Emphasis Panel - 7/25/2000Member, ZAR1 AAA-A (O2), NAIMS Special Emphasis Panel - 7/18/2001Member, ZRG GMA-1 (10), Dermatology and Rheumatology SBIRs - 10/08/2002Member, ZRG1 GMA-1 (15), Rheumatology SBIRs, 2/6/2003Member, ZRG1 GMA-1 (10&15), Dermatology and Rheumatology SBIRs -

6/17/2003 Member, ZRG GMA-1 (10), Dermatology and Rheumatology SBIRs, 10/21/2003Member, ZAR1 GHN-D (M2), Biopsycosocial Aspects of Rheumatic and

Musculoskeletal Diseases - 2/13/2004Member, ZRG1 MOSS-C (12%13), Small Business: Rheumatology and

Dermatology - 2/24/2004 Member, ZES1 LKB-E (K2), 4/7/2004Member, ZRG1 MOSS-D (13), Biology of Rheumatoid Diseases and Novel

Therapeutic Developments - 6/15/2004Member, ZRG1 MOSS-D (12), Therapeutic Developments for Dermatological

Diseases - 6/15/2004Member, ZRG1 MOSS-D (12), Small Business Skin, 3/9/2005Member, ZRG1 MOSS-D (12), Small Business Skin, 6/10/2005Member, ZAR1 EHB-M (O1), Small Research Grants (R03s) - 7/31/2006Member, ZAR1 CHW-G )J2), Multidisciplinary Clinical Research Centers (P60s)

- 10/18/2007Chair, ZDE1 RW (17), Systems Biology in Sjögren’s syndrome, 2/29/2008Member, ZRR1 Rl-1 (01), RCMI Special Emphasis Panel - 6/26/2008Member, ZRG1 GGG-M (52), Complex Human Genetics, 10/30/2008Member, ZAI1-PTM-I-M3, Autoimmunity, 01/19/2010Member, 2012/01 ZAR1 EHB (M1) 1, NIAMS Early Career Small Grants Review

Panel, October 13, 2011

7

Member, ZAR1 CHW (M1), NIAMS Clinical Trials Review Committee Panel, 21November 2011

Member, ZDE ..., NIDCR, Special Emphasis Panel - Salivary Gland Restoration,March 2012

Member, VA Immunology A Study Section, May 2012-present, Chair, 2013-present

Member, Arthritis, Connective Tissue and Skin (ACTS) - Oct 13-14, 2016 Manuscript reviewer for:

Journal of Rheumatology American Journal of HematologyArthritis and Rheumatism Annals of Internal MedicineAnalytical Biochemistry Medical LetterJournal of Immunology Journal of Clinical InvestigationClinical Immunology (formerly Molecular Medicine TodayClinical Immunology and Immunopathology) Molecular ImmunologyClinical Infectious Diseases LancetClinical and Experimental Rheumatology Immunology TodayJournal of Investigative Dermatology Tissue AntigensScandinavian Journal of Immunology Annals of the Rheumatic DiseaseMetabolism Current Opinion in TherapeuticsAmerican Journal of Human Genetics Journal of AutoimmunityScandinavian Journal of Rheumatology Endocrine PracticeArthritis Research & Therapy Clinical RheumatologyAmerican Journal of Obstetrics & Gynecology Experimental DermatologyExpert Review of Clinical Immunology Clinical EndocrinologyGenes & Immunity TherapyInternational Journal of Clinical Journal of the American Society of

Rheumatology NephrologyJournal of Physical Chemistry Arthritis Research & TherapyEuropean Journal of Clinical Investigation Experimental Eye ResearchClinical Biochemistry EndocrinologyJournal of Ancient Diseases Rheumatology (Oxford)

& Preventive Remedies LupusAmerican Journal of the Medical Sciences Journal of Pediatric NeurologyCase Reports in Medicine Lupus Science and MeidicineMedical Microbiology and Immunology Case Reports in RheuamtologyPLoS One ImmunotherapyDisease Markers MedicineScandinavian Journal of Immunology BMJ Case ReportsCase Reports in Dermatological Medicine ImmunologyInternational Medical Case Reports AntibodiesBiology of Sex Differences Frontiers of Immunology

8

Journal of the German Society of Dermatology Journal of Medical Case ReportsOral Diseases

Associate Editor, International Journal of Rheumatic Diseases, January 2013 to present

Research Support

Active

Lupus Research Institute, Novel Research Awards, “Sex disparity in lupus is driven by putativeX-linked genes,” Hal Scofield, PI, 4 year direct costs $300,000, 1/16/2016-1/15/2019.

Merit Review, Department of Veterans Affairs Medical Center, "Sex Chromosome Aneuploidesin Autoimmune disease," Hal Scofield, Principal Investigator, first year direct costs$150,000, 4 year direct costs $650,000, 4/1/2016-3/31/2020

NIH/NIAMS, 1P50AR060804, Center for Research Translation, “Oklahoma Sjögren’s SyndromeTranslational Research Center”, Hal Scofield, PI Project 3, first year direct costs $250,000, PIClinical Core, first year Direct costs $100,000, 8/1/2011-6/30/2016

NIH/NIGMS, 1 U54 GM104938-01, Center of Biomedical Research Excellence, “Oklahoma Shared Clinical and Translational Resources” Hal Scofield, Director of ClinicalResources Key Activity, first year direct costs $251,222, total direct costs $3,369,045 per year9/1/2013-9/31/2018

NIH/NIAMS, 1R03AR065786-01, PI: Eliza Chakravarty“Antibody Mediated Spontaneous Abortion in Lupus Pregnancies”, Hal Scofield, Co-PI 9/01/2014-8/31/2017

Past

National Institutes of Health, Lupus Multiplex Registry and Repository, John Harley,Principal Investigator, 9/30/06-8/29/2012, total costs $3,641,507, role on project Co-Investigator,5% effort

NIH, NIDCR, 1R01DE017561, “Sjögren's model with anti-Ro/La and Salivary Pathology andDysfunction,” Hal Scofield, Principal Investigator, 9/01/2006-8/31/2012, 5-year direct costs1,250,000

NIH, NIAMS, 1 R01AR053734-01, “The X chromosome in systemic lupus erythematosus,” HalScofield, PI, first year direct costs $250,000, 4/10/06-10/09/2011

9

NIH, NAIMS, P50, Lupus Specialized Center of Research, Morris Reichlin, PrincipalInvestigator, Hal Scofield, Project Leader, project 4, “Genetics of Severe SLE,” first year directcosts $132,500, 5 year direct costs $800,000, 9/3/02-9/2/07 with no cost extension until 9/2/2008

NIAMS, 1 K24 AR48204-01, “Mid-career clinical investigator award - genetics of severelupus,” Hal Scofield, Principal Investigator, first year direct costs $112,606, 5 year direct costs$563,030, 7/1/03-6/30/08.

NIH, Office of Health Care Disparities, P20- , “Oklahoma Center on American Indian DiabetesHealth Disparities,” Neil Henderson, PI, Hal Scofield, Project Leader, project 3, “GlucocorticoidComplications in American Indians,” first year direct costs $112,000, 9/30/2007-9/29/2008

Merit Review, Department of Veterans Affairs Medical Center, "Novel cytotoxic T cellresponses in spondyloarthropathy," Hal Scofield, Principal Investigator, first year direct costs$150,000, 4 year direct costs $547,800, 4/1/2000-3/31/2004

NIH, NIAMS, R55AR47341, "A model of Sjögren's syndrome with anti-Ro/La antibodies,"Hal Scofield, Principal Investigator, first year direct costs $40,000, 2 year direct costs $80,000(funded by the Office of Research on Women’s Health and the National Institute of Arthritisand Musculoskeletal and Skin Diseases, 9/30/01-2/28/04)

Oklahoma Center for the Advancement of Science and Technology, Health Research Award,"A model of Sjögren's syndrome with anti-Ro/La antibodies", Hal Scofield, PrincipalInvestigator, first year direct costs $45,000, 3 year direct costs $135,000, 6/1/2000-5/30/2003,20% effort

NIH, S07, “IRB Innovations in a Private Foundation,” Hal Scofield, Co-PI, first year directcosts $100,000, total costs $100,000, 9/1/02-8/31/03

National Institutes of Health, R29 FIRST-AR01844, "B27 binding peptides inspondyloarthropathy," Hal Scofield, Principal Investigator, 4/1/96-11/31/2001, total directcosts $350,000, 50% effort.

National Institutes of Health, R03, "Neonatal hepatitis and anti-Ro autoantibodies," PrincipalInvestigator Lela Lee, MD, 4/1Clinin/97-3/31/99, total direct costs $79,000, role on project Co-Investigator, 5% effort.

Oklahoma Center for the Advancement of Science and Technology, Health Research Award,HR4-015. "B27 binding bacterial peptides in spondyloarthropathy", Hal Scofield, PrincipalInvestigator, 9/1/94 - 12/31/97, $35,000 First Year Direct Costs

Arthritis Foundation-Oklahoma Chapter, Investigator Award, "HLA-B27 and Bacterial SharedSequences in Spondyloarthropathies", Principal Investigator, Hal Scofield, 1/1/92 - 12/31/92,

10

$7,500 Total Direct Costs

Oklahoma Center for the Advancement of Science and Technology, New Investigator Award,HNI-012. "Fine Specificity of Anti-Ro/SSA Autoantibodies," Hal Scofield, PrincipalInvestigator, 9/1/91 - 8/30/94, $25,000 First Year Direct Costs

National Institutes of Health, 1K11AR0844-01, "Origin of Anti-Ro/SSA Antibody", HalScofield, Principal Investigator; John Harley, Preceptor, 3/15/92 - 3/14/97, $63,408 First YearDirect Costs, 5 year total costs 345,400.

National Institutes of Health, Fogarty International Center, Senior International Fellowship,"B27-restricted T cell response to B27-mimic peptides, 1/11/98-7/11/98, total direct costs$16,100

Pending

National Institutes of Health R01, “Functional Monoclonal Antibodies from the salivary glandsof Sjögren’s syndrome”, Hal Scofield, PI, 7/1/2016-6/30/2021, first year direct costs $250,000

National Institutes of Health R01, “Curcumin in Autoimmune Lymphoproliferative Syndrome”,Hal Scofield, PI,11/1/2016-10/31/2021, first year direct costs $250,000

Patents

Peptide Diagnostics and Therapeutics for Spondyloarthopathies, US Patent number 5,719,064- issued February 17, 1998.

Peptide Diagnostics and Therapeutics for Spondyloarthopathies, European Patent number0 667 781, issued March 15, 2000.

Non-Human Animal Model for Systemic Lupus Erythematosus, US Patent number 6,232,522- issued May 15, 2001.

Publications

1. Scofield RH, Harley JB. Ro/SSA autoantigenicity is related to a nucleocapsid of vesicularstomatitis virus. Proc. Natl. Acad. Sci. (USA) 88:3343-3347, 1991.

2. Scofield RH, Dickey WD, Jackson KW, James JA, Harley JB. A common autoepitope nearthe carboxyl terminus of the 60 kD Ro ribonucleoprotein: Sequence with a viral protein. J. Clin.Immunol. 11:378-388, 1991.

11

3. Harley JB, Scofield RH. Systemic lupus erythematosus: RNA-protein autoantigens, models ofdisease heterogeneity, and theories of etiology. J. Clin. Immunol. 11:297-316, 1991.

4. Scofield H, Kaufman CE. Gastrocolic fistula mimicking the Zollinger-Ellison syndrome. Am.J. Med. Sci. 303:405-406, 1992.

5. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjögren's Syndrome and systemic lupuserythematosus. Rheum. Dis. Clin. North Am. 18:337-358, 1992.

6. Scofield, RH, Lopez, E, McNabb, S. Tularemia pneumonia in Oklahoma, 1981-1986. J OkState Med Assoc. 85:165-170, 1992.

7. Harley, JB, Scofield, RH. Aetiological Clues From the Fine Specificity of anti-Ro. Arthritisand Rheumatism Council for Research, Conference Proceedings No. 8, Fetal and NeonatalEffects Associated with Maternal Rheumatic Diseases: Insight into Disease Mechanisms,43-49, 1992.

8. Dickey, WD, van Egmond, JE, Hardgrave, KL, Harley, JB, Scofield, RH. The presence ofanti-La/SSB is associated with binding to the 13 kD carboxyl terminal of 60 kD Ro/SSA insystemic lupus erythematosus. J. Invest. Dermol. 100:412-416, 1993.

9. Hardgrave, KL, Neas, BR, Scofield, RH, Harley, JB. Antibodies to vesicular stomatitis virusproteins in systemic lupus erythematosus and normals, Arthritis Rheum. 36:962-970, 1993.

10. Scofield, RH, Warren, WL, Koelsch, G, Harley, JB. An Hypothesis for the HLA-B27Immune Dysregulation in Spondyloarthropathies: Contribution of Enteric Organisms, HLA-B27Structure, Peptides Bound by HLA-B27 and Convergent Evolution. Proc. Natl. Acad. Sci.(USA). 90:9330-9334, 1993.

11. Chambers, TL, Barber, BD, Scofield, RH. 52 kD Ro Antibody Binds Native 60 kD Ro. In:WG Thurman, ed, Fleming Scholar Reports (Oklahoma Medical Research Foundation:Oklahoma City), 1993.

12. Dickey, WD, Harley, JB, Scofield, RH. Autoantibody Production in Severe CombinedDeficiency Immunodeficiency (scid) Mice. Clin. Exp. Rheumatol. 12:157-161, 1994.

13. Scofield, RH, Harley, JB. Association of anti-Ro(SS-A) autoantibodies with glutamine inposition 34 of DQA1 and leucine in position 26 of DQB1. Arthritis Rheum. 37:961-962, 1994.

14. James, JA, Scofield, RH, Harley, JB. Charged Amino acids Predominate in the SequentialAutoantigenic Determinants of the 70K Peptide Associated with the U1 Ribonuclear Particle,Scand. J. Immunol. 39:557-566, 1994.

12

15. Inman, RD, Scofield, RH. Etiopathogenesis of ankylosing spondylitis and reactive arthritis.Current Opinion Rheum. 6:360-370, 1994.

16. Scofield, RH, Dickey, WD, Neas, BR, Horowitz, RM, Hardgrave, KL, Fujisaku, A,McArthur, R, Frank, MB, Harley, JB. Cooperative Association of T cell a Receptor and HLA-DQ Alleles for Anti-Ro in Systemic Lupus Erythematosus. Clin. Immunol. Immunopathol.72:335-341, 1994.

17. Harley, JB, Sheldon, P, Neas, B, Murphy, S, Wallace, DJ, Scofield, RH, Shaver, TS,Hardgrave-Moser, KL. Systemic Lupus Erythematosus: Considerations for a Genetic Approach.J. Invest. Dermatol. 103:144S-144S, 1994

18. Kurien BT, Scofield RH. A short, small scale preparation of plasmid DNA from E. coliusing organic solvents. Focus 16:113-114, 1994.

19. James, JA, Gross, T, Scofield, RH, Harley, JB. Immunoglobulin epitope spreading andautoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGPinduce splicesome autoimmunity. J. Exp. Med. 181:453-461, 1995.

20. Scofield, RH, Dickey, WD, Hardgrave, KL, Neas, BR, Horowitz, RM, McArthur, RA,Fujisaku, A, Frank, MB, Harley, JB. Immunogenetics of carboxyl terminal epitopes of the human60 kD Ro Autoantigen, Clin. Exp. Immunol. 99:256-261, 1995.

21. Huang, SC, Yu, H, Scofield, RH, Harley, JB. Human anti-Ro autoantibodies bind peptidesaccessible to the surface of the native Ro autoantigen. Scand. J. Immunol. 41:220-228, 1995.

22. Huang, S-C, Pan, Z, Kurien, BT, James, JA, Harley, JB, Scofield, RH. Immunization withvesicular stomatitis virus nucleocapsid protein induces autoantibodies to the 60 kD Roribonucleoprotein particle. J. Invest. Med. 43:151-158, 1995.

23. Beall, D, Scofield, RH. Milk alkali syndrome associated with calcium carbonateconsumption: Report of seven patients with PTH levels and an estimate of the prevalence amongpatients hospitalized with hypercalcemia. Medicine (Baltimore) 74:89-96, 1995.

24. Kurien BT, Scofield RH. Polyethylene glycol mediated bacterial colony transformation.Biotechniques 18:1023-1026, 1995.

25. Scofield, RH, Kurien, BT, Gross T, Warren WL, Harley, JB. HLA-B27 binds a peptide fromits own sequence as well as selected similar bacterially-derived peptides: Implications for thepathogenesis of spondyloarthropathies. Lancet 345:1542-1544, 1995.

26. Harley JB, Scofield RH. The spectrum of ankylosing spondylitis. Hosp Prac 30:37-46,1995.

13

27. Cofie, DQ, Rodgers, R, Draelos, MT, Olansky, L, Scofield, RH. The syndrome of type IIpolyglandular autoimmunity associated with HLA-DR4 in a large kindred, including HLA-DR3/DR4 in the probands, a pair of identical twins with identical manifestations. EndocrinePractice 1:395-398, 1995.

28. Scofield, RH, Fogle, M, Rhoades, ER, Harley, JB. Rheumatoid arthritis in a United StatesPublic Health Service Hospital. The manifestations of rheumatoid arthritis vary among tribalgroups. Arthritis Rheum 39:283-286, 1996.

29. Scofield, RH. Hormone Action. In: McKee, PA, Kaufman, CE, eds, Essentials ofPathophysiology (New York: Little, Brown and Co.), pp 221-230, 1996.

30. Scofield, RH. Thyroid. In: McKee, PA, Kaufman, CE, eds, Essentials of Pathophysiology(New York: Little, Brown and Co.), pp 267-276, 1996.

31. Scofield, RH, Henry, WH, Kurien, BT, James, JA, Harley, JB. Immunization with shortpeptides derived from the systemic lupus erythematosus associated 60 kD Ro autoantigen resultsin anti-Ro ribonucleoprotein autoimmunity. J Immunol 156:4055-4066, 1996.

32. Scofield, RH. Leporidae's Revenge. Patient Care 30:171-172, 1996.

33. Scofield, RH, Zhang, F-C, Kurien, BT, Anderson CJ, Reichlin, M, Harley, JB, Stafford, HA.Development of the anti-Ro response in systemic lupus erythematosus. Arthritis Rheum39:1664-1668, 1996.

34. Reichlin, M, Scofield, RH. Ro (SS-A) antibodies. In: Shoenfeld, Y, Peter, JB, eds, Textbookof Autoantibodies (Elsevier:Amsterdam), pp 783-788, 1996.

35. Scofield, RH. Autoimmune thyroid disease in systemic lupus erythematosus and Sjögren'ssyndrome. Clin Exp Rheumatol 14:321-330, 1996.

36. Swartz, MA, Scofield, RH, Dickey, WD, Kirk, JL, Wilson, DA, Pitha, JV, Muchmore, HG.Unilateral Adrenal Enlargement Due to Histoplasma capsulatum. Clin Infect Dis 23:813-815,1996.

37. Pierce, P, Kurien, BT, Scofield, RH. Acquired Autoimmunity to the Ro ribonucleoprotein inmice immunized with the 480-494 Ro peptide. In: WG Thurman, ed, Fleming Scholar Reports(Oklahoma Medical Research Foundation: Oklahoma City), pp 83-92, 1996.

38. Schnitz, W, Taylor-Albert, E, Targoff, IN, Reichlin, M, Scofield, RH. Anti-PM/Sclautoantibodies in patients without polymyositis or scleroderma. J Rheumatol 23:1729-1733,1996.

14

39. Scofield, AN, Scofield, AK, Scofield, RH. On hirsutism in a doll population. JIrreproducible Results 41:6-7, 1996 (also, honorifically included as - Scofield, AN, Scofield,AK, Scofield, RH. On hirsutism in a doll population. In: Scherr GH and Glenn J, eds, The Bestof the Journal of Irreproducible Results II (Barnes & Noble Press:New York), pp133-134,1997).

40. Scofield, RH. Etiopathogenesis of spondyloarthropathies. Curr Opinion Rheumatol 8:309-315, 1996.

41. Scofield, RH. Tolerance and B27 presentation. In: López-Larrea, C, ed., Immunogenetics ofSpondyloarthropathies. HLA-B27 and Ankylosing Spondylitis (RG Landes:New York), pp183-195, 1997.

42. Kurien, BT, Scofield, RH, Broyles, RH. Efficient 5' end labeling of dephosphorylated DNA.Anal Biochem. 245:123-126, 1997.

43. Huang, S-C, Scofield, RH, Kurien, BT, Harley JB. Human autoantibodies bind multipleconformational epitopes of the 60 kD Ro/SSA autoantigen. J Clin Immunol 17:212-219, 1997.

44. Goddard, R, Scofield, RH. Right pneumothorax with the S1Q3T3 electrocardiogram patternusually associated with pulmonary embolus. Am J Emerg Med 15:310-312, 1997.

45. Kurien, BT, Moore, KL, Scofield, RH. Anti-Ro/SSA antibodies bind the surface ofgranulocytes. Ann New York Acad Sci 815:481-483, 1997.

46. James, JA, Scofield, RH, Harley, JB. Lupus humoral autoimmunity after short peptideimmunization. Ann New York Acad Sci 815:124-127, 1997.

47. Scofield, RH, Kurien, BT, Reichlin M. Immunologically restricted, inhibitory anti-Ro inmonozygotic twins. Lupus 6:395-398, 1997.

48. Kurien, BT, Scofield, RH. Multiple immunoblots after non-electrophoretic bidirectionaltransfer of a single SDS-PAGE gel with multiple antigens. J Immunol Method 205:91-94, 1997.

49. Scofield, RH, Zhang, F-C, Kurien, BT, Harley. Anti-Ro specificity defined by multipleantigenic peptides identifies the components of tertiary epitopes. Clin Exp Immunol 109:480-487, 1997.

50. Kurien, BT, Scofield, RH. Multiple nuclear dot antinuclear antibodies in patients withoutprimary biliary cirrhosis Indian J Biochem Biophys 35:41-47, 1998.

51. Arbuckle, MR, Gross, T, Scofield, RH, Hinshaw, LB, Harley, JB, James, JA. Lupus humeralautoimmunity induced by short peptide immunization in a baboon model. J Invest Med 46:58-

15

65, 1998.

52. Baker, MZ, Scofield, RH. Educational needs of internal medicine residency graduates:general internists versus subspecialists. Med Education 32:527-532, 1998.

53. Kurien, BT, Scofield, RH. Immunoblotting of multiple antigenic peptides. Electropheresis19:1659-1661, 1998.

54. Ford, AL, Kurien, BT, Harley, JB, Scofield, RH. Analysis of development of anti-centromereautoantibody in a patient evolving from a lupus/Sjögren's overlap to the CRESTvariant of scleroderma. J Rheumatol 25:1419-1424, 1998.

55. Kurien, BT, Scofield, RH. Enhanced heat mediated quick Coomassie Blue protein stainingand destaining enhances detection sensitivity. Ind J Biochem Biophys 35:385-389, 1998

56. Scofield, RH, Tardibono, G, Ogden, SB, Harley, JB, Reichlin, M, Kurien, BT. Rheumatoidhyperviscosity: Analysis of a patient with blocking intermediate complexes and a review of theliterature. Semin Arthritis Rheum 27:382-391, 1998.

57. Kurien BT, Scofield RH. Notes & Tips: Long term storage of sodium dodecyl sulfate-polyacrylamide gels in polyethylene bags. Anal Biochem 261:116-118, 1998

58. Scofield RH, Farris AD, Horsfall AC, Harley JB. Fine Specificity of the Immune Responseto the Ro/SSA Ribonucleoprotein. Arthritis Rheum 42:199-209, 1999.

59. Kurien, BT, Scofield, RH. Mouse urine collection using clear plastic wrap. Lab Animals33:83-86, 1999.

60. Farris, DA, Harley, JB, Reynolds, P, James JA, Scofield, RH, Brown, L, McCluskey J,Gordon, TP. Induction of autoimmunity by multivalent immunodominant and subdominant Tcell determinants of La(SS-B). J Immunol 162:3079-3087, 1999

61. Scofield, RH, Kaufman, KM, Baber, U, James, JA, Harley, JB, Kurien BT. Immunization ofmice with human 60 kD Ro peptides results in epitope spreading if the peptides are highlyhomologous between man and mouse. Arthritis Rheum 42:1017-1024, 1999.

62. Scofield RH, Kurien BT, Zhang F-C, Metha P, Kaufman K, Gross T, Bachmann M, Gordon,T, Harley JB. Protein-protein interaction of the Ro-ribonucleoprotein particle using multipleantigenic peptides. Mol Immunol. 36:1093-1106, 1999.

63. Scofield, RH, James, JA. Immunization as a model of systemic lupus erythematosus. SemArthritis Rheum 29:140-147, 1999.

16

64. Scofield, RH, Racila, DM, Kurien, BT, Sontheimer, RD. Anti-calreticulin segregates anti-Rosera in systemic lupus erythematosus: anti-calreticulin is present in sera with anti-Ro alone butnot in anti-Ro sera with anti-La or anti-RNP. J Rheumatol 27:128-134, 2000

65. Scofield RH. Diseases of the immune and collagen vascular systems. In, Rhoades ER, ed.,The Health of American Indians and Alaska Natives (Johns Hopkins Press: Baltimore, MD),pp 328-346, 2000

66. Kurien, BT, Newland, J, Paczkowski, C, Moore, KL, Scofield, RH. Association ofneutropenia in systemic lupus erythematosus with anti-Ro and binding of an immunologicallycrossreactive neutrophil membrane antigen. Clin Exp Immunol 120:209-217, 2000.

67. Harley, JB, Scofield, RH, James, JA. Molecular Mimicry in Systemic Lupus Erythematosus.In, Cunningham, C, Fujinami, R, eds, Molecular Mimicry and Autoimmunity (AmericanSociety of Microbiology Press:Washington, DC), pp 109-126, 2000.

68. Kurien BT, Chambers TL, Thomas PY, Frank MB, Scofield, RH. Autoantibody to theleucine zipper region of 52 kD Ro/SSA binds native 60 kD Ro/SSA: Identification of thecomponent parts of the tertiary epitope in 60 kD Ro. Scand J Immunol 53:268-276, 2001

69. Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, Baird T, Hutchings D,Bruner G, Scofield RH, Moser K, Harley JB. Linkage analysis of angiotensin-convertingenzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol CellEndocrinol 177:81-85, 2001.

70. Scofield RH. Milk-alkali syndrome. In, Shenker Y, Talavera F, Wilber JF, Plantz SH, ZevitzME, eds, Textbook of Medicine (emedicine.com) and Emedicine Journal volume 2, June 21,2001

71. Scofield AN, Kurien BT, Scofield RH. Can epitopes of 60 kD Ro distinguish systemic lupuserythematosus from Sjögren's syndrome? Lupus 10:547-553, 2001

72. Kurien BT, Kaufman KM, Scofield RH. Pellet pestle homogenization of agarose gel slices at450 C for deoxyribonucleic acid extraction. Anal Biochem 296:162-166, 2001

73. James JA, Harley JB, Scofield RH. Role of viruses for Systemic Lupus Erythematosus andSjögren’s Syndrome. Curr Opin Rheumatol 13:370-376, 2001

74. Nath SK, Kelly JA, Namjou B, Lam T, Bruner GR, Scofield RH, Aston CE, Harley JB.Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet 69:14-1-1406, 2001

75. Scofield RH, Sadanandan P. Arthritis as a Manifestation of Systemic Disease. In, Lohr KM,

17

Talavera F, Brent LH, Plantz SH, Zevitz ME, eds, Textbook of Medicine (emedicine.com),2001

76. Howell P, Kariampuzha S, Kipgen W, Baker MZ, Williams GR, Title T, Scofield RH. Non-surgical therapy of primary hyperparathyroidism: experience at a low volume institution. J OklaState Med Assoc, 94:561-565, 2001.

77. Kurien BT, Matsumoto H, Scofield RH. Purification of tryptic peptides for massspectroscopy using polyvinylidene fluoride membrane. Ind J Biochem Biophys. 38:274-6, 2001.

78. Scofield RH. Seronegative Arthropathies. In, King, RA, Wotulsky, A, Rotter, J, eds, TheGenetic Basis of Common Diseases, 2nd ed (Oxford University Press:London), 604-612, 2002.

79. Kangasegar S, Cimaz R, Kurien BT, Scofield RH. Neutropenia in neonatal lupus. JRheumatol 29:187-191, 2002.

80. Kurien BT, Scofield RH. Extraction of nucleic acid fragments from gels. Anal Biochem302:1-9, 2002.

81. Gillian M, Scofield RH, Harley JB. Hashimoto’s thyroiditis presenting as bilateral kneearthropathy. J Okla State Med Assoc 95:323-325, 2002.

82. Kelly JA, Thompson K, Kilpatrick J, Lam T, Nath SK, Gray-McGuire C, Reid J, Bruner GR,Scofield RH, Harley JB. Evidence for a susceptibility gene (SLEH1) on chromosome 11q14 forsystemic lupus erythematosus families characterized by hemolytic anemia. Proc Natl Acad Sci(USA) 99:11766-11771, 2002.

83. Kaufman KM, Kelly JA, Harley JB, Scofield RH. A genetic marker within the CD44 geneconfirms linkage at 11p13 in African-American families with lupus manifested bythrombocytopenia, but association of CD44 is not present. Gene Immunity 1(Suppl3):S86-S88,2002.

84. Kurien BT, Hensley KM, Ganick S, Bachmann M, Scofield RH. Oxidative Modification ofAutoantigens. In, Conrad R-L, Bachmann M, eds, From Proteomonics to MolecularEpidemiology: Relevance of Autoantibodies: Report of the 7th Dresden Symposium onAutoantibodies (Lengerich:Berlin), pp 161-180, 2002.

85. Scofield RH, Pierce PG, James JA, Kaufman KM, Kurien BT. Immunization with peptidesfrom 60 kD Ro in diverse mouse strains. Scand J Immunol 56:477-483, 2002.

86. McClain MT, Scofield RH, Kurien BT, Gross TF, James JA. Selective antigenic peptides arecapable of inducing wide-spread autoimmunity which closely mimics the humeral fine specificityof human SLE. Scand J Immunology 56:399-407, 2002.

18

87. Kurien BT, Scofield RH. Heat mediated, ultra-rapid electrophoretic transfer of high and lowmolecular weight proteins to nitrocellulose membranes. J Immunol Meth 266:127-133, 2002.

88. Scofield, RH, Bruner GR, Kelly J, Bacino D, Harley JB. Thrombocytopenia identifies asevere systemic lupus erythematosus phenotype and shows genetic linkage to multipleindependent chromosomal regions. Blood 101:992-997, 2003 (published online atwww.bloodjournal.org on 12 Sept 2002).

89. Kurien BT, Scofield RH. Protein Immunoblotting: a review. J Immunol Meth 274:1-15,2003.

90. Heinlen LD, Kim X, McClain MT, Quintero A, Harley JB, James JA, Scofield RH.Characterization of the anti-Ro and anti-RNP response in unaffected family members of SLEpatients. Lupus 12:335-337, 2003.

91. Arbuckle MR, McClain MT, Rubertsen M, Scofield RH, Dennis G, James JA, Harley JB.Autoantibodies are present years before the clinical onset of systemic lupus erythematosus. NewEngl J Med 349:1526-1533, 2003.

92. Sawalha A, Potts R, Schmid WR, Scofield RH, Harley JB The Genetics of PrimarySjögren’s Syndrome, Curr Rheumatol Report 5:324-332, 2003.

93. Kurien BT, Scofield RH. Free radical mediated peroxidative damage in systemic lupuserythematosus. Life Sciences 73:1655-1666, 2003

94. Scofield RH. Knock out of a lupus autoantigen produces lupus. Trend Immunol. 25:1-3,2004.

95. Shenoi J, Kurien BT, Kurono S, Mascarenhas R, Matsumoto H, Scofield RH. Cost-benefitanalysis of a method using diatomaceous earth to purify Tamm-Horsfall protein. BioTechniques36:64-66, 2004

96. Nath SK, Namjou B, Kilpatrick J, Garriott P, Bruner G, Scofield RH, Harley JB. A CandidateRegion on 11p13 for Systemic Lupus Erythematosus (SLE) Susceptibility Gene Identified inAfrican-American SLE families, Ascertained Through the Presence of Discoid Lesion. J InvestDermatol 9:64-67, 2004

97. Scofield RH. Rapid Review: Autoantibodies as predictors of disease. Lancet 363:1544-1546, 2004.

98. Scofield RH. Milk-alkali syndrome. In, Pourmotabbed G, Talavera F, Khardori R, CooperM, Griffing GT,, eds, Medicine Specialties: Endocrinology (emedicine.com), February 5,2004.

19

99. Kurien BT, Porter A, Patel N, Kurono S, Matsumoto H, Scofield RH. Mechanized syringe-homogenization of human and animal tissue. Assay Drug Dev Technol 2:1-5, 2004

100. Nath SK, Kelly JA, Harley JB, Scofield RH. Mapping the Systematic Lupus Erythematosus(SLE) Susceptibility Genes. Methods Mol Med 102:11-30, 2004

101. Kurien BT Patel NC, Porter AC, Kurono S, Matsumoto H, Wang H, Scofield RH.Determination of prolidase activity using matrix assisted laser desorption ionization time of flightmass spectrometry. Anal Biochem 331:224-229, 2004

102. Kurien BT, Scofield RH, Hensley KM. SOD1 interacts directly with hemoglobin in vitro.Thrombosis Haem 92:218-220, 2004

103. Scofield RH. And she knew it too. Blood and Thunder: Musing on the Art of Medicine4:135-136, 2004.

104. Kurien BT, Everds NE, Scofield RH. Experimental animal urine collection - a review. LabAnimal 38:333-361, 2004

105. Scofield RH, Kurien BT, Gross J, Reed NB, Taylor AK, Dominguez N, Mehta P,Bachmann M. Interaction of calcium and Ro60: Increase of antigenicity. Mol Immunol 41:809-816, 2004

106. Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic Epidermal Necrolysis-like Acute Cutaneous Lupus Erythematosus and the Spectrum of the Acute Syndrome ofApoptotic Pan-Epidermolysis (ASAP) – A Case Report, Concept Review, and Proposal for NewClassification of Lupus Erythematosus Vesiculobullous Skin Lesions Lupus 13:941-950, 2004

107. Scofield RH. Autoantibodies as predictors of disease (erratum). Lancet 364:1756, 2004

108. Kurien BT, Patel NC, Porter AC, Kurono S, Matsumoto H, Wang H, Scofield RH.Determination of prolidase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy. Anal Biochem 331:224-229, 2004

109. Kurien BT and Scofield RH. Electrophoresis: Blotting Techniques. In, Worsfold P,Townshend A, Poole C, eds, Encyclopedia of Analytical Science, 2nd edition(Elsevier:Oxford), pp 425-444, 2004

110. Scofield RH, Kurien BT, Ganick S, McClain, Pye Q, James JA, Schneider RI, Broyles RH,Bachmann M, Hensley KM. Modification of the lupus-associated 60 kDa Ro protein with lipidoxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading,Free Radical Biol Med 38:719-728, 2005

20

111. Scofield RH, Asfa S, Obeso D, Jonsson R, Kurien BT. Immunization with short peptidesfrom the 60 kD Ro/SSA antigen recapitulates the serological and pathological findings as well asthe salivary gland dysfunction of Sjögren’s syndrome. J Immunol 175:8409-8414, 2005

112. Kurien BT, Asfa S, Li C, Dori Y, Jonsson R, Scofield RH. Induction of oral tolerance inexperimental autoimmunity. Scand J Immunol 61:418-425, 2005

113. Namjou B, Kelly JA, Kilpatrick J, Kaufman KM, Scofield RH, Harley JB. Linkage at5q14.3-15 in pedigrees multiplex for systemic lupus erythematosus (SLE) stratified byautoimmune thyroid disease (AITD). Arthritis Rheum 52:3646-3650, 2005

114. Kurien BT, Scofield RH. In vitro modification of solid phase multiple antigenicpeptides/autoantigens with 4-hydroxy-2-nonenal (HNE) provides ideal substrates for detection ofanti-HNE antibodies and peptide antioxidants. J Immunol Methods 303:66-75, 2005 (PMID:16055145)

115. Kurien BT, Gross T, Scofield RH. Barbering in mice: a model of trichotillomania? Br MedJ 331:1503-1505, 2005

116. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry insystemic lupus erythematosus. Autoimmunity 39:1-8, 2006

117. Wang H, Kurien BT, Lundgreen D, Patel NC, Kaufman KM, Miller DS, Porter AC,D’Sousa A, Nye L, Tumbush J, Kerr DS, Kurono S, Matsumoto H, Scofield RH. A nonsensemutation of PEPD in four Amish children with prolidase deficiency. Am J Med Genet140:580-585, 2006

118. Beall DP, Henslee HB, Webb HR, Scofield RH. Milk alkali syndrome: Historical reviewand description of the modern version of the syndrome. Am J Med Sci 331:233-242, 2006

119. Scofield RH. Milk-alkali syndrome. In, Pourmotabbed G, Talavera F, Khardori R, CooperM, Griffing GT,, eds, Medicine Specialties: Endocrinology (emedicine.com), 2006

120. Reichlin, M, Scofield, RH. Ro (SS-A) antibodies. In: Shoenfeld Y, Gershwin ME, andMeroni PL, eds, Textbook of Autoantibodies, 2nd ed, (Elsevier:Amsterdam), 2006

121. Kurien BT, Scofield RH. Western Blotting. Methods 38:283-293, 2006. (PMID:16483794)

122. Addington S, Larsen N, Scofield RH. Milk-alkali syndrome in pre-eclamptic pregnancy. JOkla St Med Assoc 99:480-484, 2006

123. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus

21

erythematosus. Scand J Immunol 64:227-235, 2006

124. Kurien BT, Patel NC, Porter AC, Miller D, D’Sousa A, Matsimoto H, Wang H, ScofieldRH. Prolidase deficiency and biochemical assays used in its diagnosis. Anal Biochem349:165-175, 2006

125. Kurien BT, Scofield RH. Lipid peroxidation in SLE. Indian J Exp Biol 44:349-356, 2006.

126. Scofield RH. Poor, Poor Thing. Blood and Thunder: Musing on the Art of Medicine.6:106-108, 2006.

127. Zacharias L, Scofield RH. Rheumatic Manifestations of Systemic Disease. In, Lohr KM,Talavera F, Brent LH, Plantz SH, Zevitz ME, eds, Textbook of Medicine (emedicine.com), 2006

128. James JA, Harley JB, Scofield RH. Epstein Barr virus and Systemic Lupus Erythematosus.Curr Opin Rheumatol 18:462-467, 2006

129. Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens inautoimmune diseases. Free Rad Biol Med 41:549-556, 2006

130. Scofield RH, Bruner GR, Harley JB, Namjou B. Autoimmune thyroid disease is associatedwith secondary Sjögren’s syndrome in familial systemic lupus. Ann Rheum Dis 66:410-413,2007 (Epub August 24, 2006 at http://ard.bmjjournals.com)

131. Kurien BT, Scofield RH. Curcumin/tumeric solubilized in sodium hydroxide inhibits HNEprotein modification. J Ethnopharmacol 110:368-373, 2007

132. Kamble S, Kem D, Baker MZ, Scofield H, Lyons T, Olansky L. Thymic neuroendocrinetumor presenting as Cushing’s syndrome: A case report and review of current literature.EndoTrends 14:10-11, 2007

133. Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses used totreat osteoarthritis worsens insulin resistance. Am J Med Sci 333:333-339, 2007

134. Kurien BT, Scofield RH. Four men in a space station - to say nothing of the cow!: thequest for finding respite and work in the ultimate frontier. Med Hypotheses 68:1195-1199, 2007

135. Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility andpharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 5:567-576,2007

136. Kurien BT, Mathews SA, Scofield RH. Can low dose diagnostic dental radiation trigger

22

Sjögren's syndrome? Medical Hypotheses 69:995-1000, 2007 (Epub 2007 Apr 17)

137. Blevins S, Leyva, MJ, Wright JE, Scofield RH, Aston CE. Effect of Cinnamon on Glucoseand Lipid Levels in Non-insulin Dependent Type 2 Diabetes Mellitus. Diabetes Care30:2236-2237, 2007

138. Williams PH, Cobb BL, Namjou B, Scofield RH, Sawalha AH, Harley JB. Horizons inSjögren's Syndrome Genetics. Clin Rev Allergy Immunol 32:201-209, 2007 (Epub ahead ofprint 26 Oct 2007)

139. Tauseef A, Greenfield RA, Scofield RH, Bronze MS. Gatifloxacin –AssociatedHypoglycemia. J Okla St Med Assoc 100:425-428, 2007

140. Pham T, Pesina J, Scofield RH. 13-cis-retinoic acid induction of clinical polycystic ovariandisease. Endocr Prac 13:776-779, 2007

141. Malik S, Bruner GR , Williams-Weese C, Feo L, Scofield RH, Reichlin M, Harley JB,Sawalha AH. The presence of anti-La autoantibody is associated with a lower risk of nephritisand seizures in lupus patients. Lupus 16:863-866, 2007

142. Kurien BT, Scofield RH. Autoimmune diseases and oxidatively modified autoantigensAutoimmunity Rev 7:567-573, 2008. Epub 2008 May 27. (PMCID:PMC2585037)

143. Scofield RH. Autoimmune hypo- and hyperthyroid in systemic autoimmune disease. In,Walker SE, Jara LJ, eds, Handbook of Systemic Autoimmune Diseases: EndocrineManifestations of Systemic Autoimmune Disease 9:195-205, 2008 (No PMCID required)

144. Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren’s syndrome. J DentRes 87:308-318, 2008 (No PMCID required)

145. Sawalha AH, Webb R, Han S, Kelly JA, Kaufman KM, Kimberly RP, Alarcón-RiquelmeME, James JA, Vyse TJ, Gilkeson G, Choi C-B, Scofield RH, Bae S-C, Nath SK, Harley JB.Common variants within MECP2 confer risk of systemic lupus erythematosus. PloS ONE5;3:e1727, 2008 (PMCID:PMC2253825)

146. Kurien BT, Scofield RH. Sjögren’s syndrome. In, BMJ Point of Care, 2008(www.epocrates.com) (No PMCID required)

147. Kurien BT, D’sousa A, Rodgers R, Shenoi J, Kurono S, Matsumoto H, Asfa S, Hensley K,Scofield RH. Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the association of a polymorphism in its promoter region as a risk factor in SLE. BMCMed Genet 9:62, 2008. (PMCID:PMC2474584)

23

148. Kamen DL, Shaftman SR, Barron M, Parker TM, Bruner GR, Aberle T, James JA, ScofieldRH, Harley JB, Gilkeson GS, Autoantibody Prevalence and Lupus Disease Characteristics in aUnique African American Population. Arthritis Rheum 58:1237-1247, 2008 (No PMCIDrequired)

149. Scofield RH, Bruner GR, Kelly J, Harley JB. Klinefelter's syndrome (47,XXY) in malesystemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the Xchromosome. Arthritis Rheum 58:2511-2517, 2008. (PMCID:PMC2824898) (reviewed andrecommended by Faculty of 1000)

150. Kurien BT, Scofield RH. 4-Hydroxynonenal-modified Ro 60 autoantigen acceleratesautoimmunity in experimental animals. Rheumatol (Oxford) 47:1587, 2008 (No PMCIDrequired)

151. Kurien BT, Scofield RH. Lipstick consumption and systemic lupus erythematosus: Nothingto gloss over. Clin Rheumatol 27:1339-1340, 2008. Epub 2008 Jul 19 (No PMCID required)

152. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, Hervé M, Meffre E, OscierDG, Vlassara H, Scofield RH, Chen Y, Allen SL, Rai KR, Chu CC, Chiorazzi N. Chroniclymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and chemicaloxidation. Mol Med 14:665-674, 2008. (PMCID:PMC2582860)

153. Canzler U, Bartsch H, Kurien BT, James JA, Scofield RH, Grossmann K, Lehmann W,Pillarsky C, Denz A, Grützmann R, Conrad K, Schmitz M, Rieber EP, Distler W, Bachmann MPDetection of autoantibodies to tumor-associated antigens in sera of patients with systemicautoimmunity using a novel protein microblot array. Scand J Immunol 69:563-569, 2009. (NoPMCID required)

154. Cooney CM, Bruner GR, Aberle T, Namjou-Khales B, Myers LK, Feo L, Li S, D'Souza A,Ramirez A, Harley JB, Scofield RH. 46,X,del(X)(q13) Turner's syndrome women with systemiclupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 10:478-481, 2009. Epub2009 May 21. (PMCID:PMC2722751)

155. Namjou B, Sestak AL, Armstrong DL, Zidovetzki R, Jacob N, Ciobanu V, Kaufman KM,Kelly JA, Ojwang JO, Quismorio F, Reiff A, Myones BL, Guthridge JM, Nath SK, Bruner GR,Mehrian-Shai R, Silverman E, Klein-Gitelman M, McCurdy D, Wagner-Weiner D, Nocton J,Putterman C, Bae S-C, Kimberly RP, Vyse TJ, Gilkeson GS, Kamen D, Alarcón-Riquelme ME,Langefeld CD, Gaffney PM, Moser KL, Merrill JT, Scofield RH, James JA, Harley JB, JacobCO. Robust Association of STAT4 with Systemic Lupus Erythematosus in Four Different RacialGroups. Arthritis Rheum 60:1085-1095, 2009. (PMCID:PMC2776081)

156. Gomez-Mejiba SE, Pye Q, Kurien BT, Akram H, Zhai Z, Hensley M, Scofield RH,Ramirez DC. Inhalation of Environmental Stressors & Chronic Inflammation: Autoimmunity and

24

Neurodegeneration. Mutat Res 674:62-72, 2009. (PMCID:PMC2676865)

157. Kurien BT, Scofield RH. Heat-solubilized curcurmin should be considered in clinical trialsfor increasing bioavailability. Clin Cancer Res 15:474, 2009 (No PMCID required)

158. Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA, Kaufman KM, Dominguez N, Klein W,Kim-Howard X, Bruner GR, Scofield RH, Moser KL, Gaffney PM, Dozmorov IM, Gilkeson GS,Wakeland EK, Li QZ, Langefield CD, Marion MC, Williams AH, Alarcón GS, Kimberly RP,Edberg JC, Ramsey-Goldberg R, Reveille JD, McGwin G, Vila LM, Petri MA, Vyse TJ, MerrillJT, Gregersen PK, James JA, Nath SW, Harley JB, Guthridge JM. Replication of the BANK1genetic association with systemic erythematosus in a European-derived population. GeneImmunity 10:531-538, 2009 (PMCID:PMC2736873)

159. Kurien BT, Scofield RH, eds., Methods in Molecular Biology: Protein Blotting andDetection (Human Press: London), volume 536, 2009. (No PMCID required)

160. Scofield RH, Nguyen TT. Milk-alkali syndrome. In, Pourmotabbed G, Talavera F, KhardoriR, Cooper M, Griffing GT,, eds, Medicine Specialties: Endocrinology (emedicine.com), 2009(No PMCID required)

161. Kurien BT, Scofield RH. Oral administration of heat-solubilized curcumin for potentiallyincreasing curcumin bioavailability in experimental animals. Int J Cancer. 2009 Apr 27. (NoPMCID required)

162. Selby GB, Mosallaei-Benjamin M, Kalyanaraman V, Lancaster A, Scofield RH.Difficulties in monitoring the glucose status of patients undergoing hematopoietic stem celltransplantation. Biol Blood Marrow Transplant. 15:1000, 2009. (No PMCID required)

163. Kurien BT, Scofield RH. Curry spice curcumin and prostate cancer. Mol Nutr Food Res.53:939-940, 2009. (No PMCID required)

164. Kurien BT, Scofield RH. Increasing aqueous solubility of curcumin for improvingbioavailability. Trends Pharmacol Sci. 30:334-335, 2009. Epub 2009 Jun 10. (No PMCIDrequired)

165. Sawalha AH, Harley JB, Scofield RH. Autoimmunity and Klinefelter's syndrome: whenmen have two X chromosomes. J Autoimmun. 33:31-34, 2009. Epub 2009 May 22.(PMCID:PMC2885450)

166. Kurien BT, Scofield RH. Bubbling hookah smoke through heat-solubilizedcurcumin/turmeric and incorporation of the curry spice as an additive or filter in cigarettes tominimize tobacco smoke-related toxicants. Med Hypotheses. 73:462-463, 2009. Epub 2009May 10. (No PMCID required)

25

167. Kurien BT, Scofield RH. Increasing the solubility of the nutraceutical curcumin by heat andinhibition of oxidative modification. Mol Nutr Food Res. 53:308, 2009. (No PMCID required)

168. Kurien BT, Scofield RH. Heat-solubilized curcumin should be considered in clinical trialsfor increasing bioavailability. Clin Cancer Res 15:747, 2009. (No PMCID required)

169. Scofield RH. Genetics of Systemic Lupus Erythematosus and Sjögren’s Syndrome. CurrOpin Rheum 21:448-453, 2009. (No PMCID required)

170. Namjou B, Scofield R, Kelly J, Goodmon E, Aberle T, Bruner G, Harley J. The effects ofprevious hysterectomy on lupus. Lupus. 2009;18:1000-1005, 2009. (PMCID:PMC2769169)

171. Scofield RH, Oates JC. The place of William Osler in the description of systemic lupuserythematosus. Am J Med Sci 338:409-412, 2009. (PMCID:PMC2783313)

172. Dillon SP, D’Souza A, Kurien BT, Scofield RH. Systemic lupus erythematosus and C1q: Aquantitative ELISA for determining C1q levels in serum. Biotechnol J. 5:337, 2010(PMCID:PMC2829988).

173. Aggarwal R, Sestak AL, D’Souza A, Dillon SP, Namjou B, Scofield RH. Complementdeficiency in a large cohort of familial systemic lupus erythematosus. Lupus 19:52-57, 2010(PMCID: PMC2824327)

174. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weissman MH. Review: Male systemiclupus erythematosus: a review of sex disparities in this disease. Lupus 19:119-129, 2010. (NoPMCID required)

175. Aggarwal R, Namjou B, Li S, D’Souza A, Tsao BP, Bruner B, James JA, Scofield RH.Male only systemic lupus. J Rheumatol 37:1480-1487, 2010 (PMCID:PMC2978923)

176. Lee YJ, Scofield RH, Hyon JY, Yun P-Y. Lee H-J, Lee EY, Lee EB, Song YW. Salivarychemokine levels in patients with Sjögren’s syndrome. Rheumatol 49:1747-1752, 2010(PMCID:PMC2919196)

177. Scofield RH. Do we need new autoantibodies in lupus? Arthritis Res Therapy. 12:120,2010 (PMCID:PMC2911855)

178. Dorri Y, Kurien BT, Scofield RH. Problems with multiple use of transfer buffer in proteinelectrophoresis transfer. J Biomol Tech 21:1-2, 2010 (PMCID:PMC2841995)

179. Bippes CC, Feldmann A, Stamova S, Cartellieri M, Schwarzer A, Wehner R, Schmitz M,Riber EP, Zhao S, Schäkel K, Temme A, Scofield RH, Kurien BT, Bartsch H, Bachmann M.A Novel Modular Antigen Delivery System for Immunotargeting of Human 6-sulfo LacNAc-

26

Positive Blood Dendritic Cells (SlanDCs). PLoS One 21:e16315, 2011 (PMCID:PMC3025022)

180. Rasmussen A, Sevier S, Kelly J, Glenn S, Aberle T, Cooney CM, Grether A, Goodmon E,Ning J, Tesiram J, Morrisey J, Powe T, Drexel M, Daniel W, Namjou B, Ojwang JO, NguyenKM, Cavett JW, Te JL, James JA, Scofield RH, Moser KL, Gilkeson GS, Kamen DL, Carson C,Ballesteros MdC, Punaro MG, Quintero-del-Rio AL, Karp DR, Wallace DJ, Weisman M, MerrillJ, Rivera R, Petri MA, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM,Bruner GR, Harley JB. The Lupus Family Registry and Repository. Rheumatol 50:47-59, 2011(PMCID:PMC3307518)

181. Scofield RH. Viewpoints in Genetic Medicine: Can Genetic Changes PredictManifestations of SLE? In, Beuhler B, ed. Medscape Genomic Medicine, 2011 (no PMCIDrequired)

182. Dillon S, Aggarwal R, Harding JW Jr, Li L-J, Weissman MH, Li S, Cavett JW, Sevier ST, Ojwang JW, D’Souza A, Harley JB, Scofield RH. Klinefelter’s syndrome (47,XXY) among menwith systemic lupus erythematosus. Acta Paediatrica 100:819-823, 2011

183. Rittenhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, DedekeAB, . Harley JB, Scofield RH, Guthridge JM, James JA. Extended report: Vitamin D deficiencyis associated with an increased autoimmune response in healthy individuals and in patients withsystemic lupus erythematosus. Ann Rheum Dis 70:1569-1574, 2011. (Published Online First: 17May 2011) (reviewed and recommended by Faculty of 1000) (PMCID:PMC3149865)

184. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, Alarcón-Riquelme ME,Gallant CJ, Boackle SA, Criswell LA, Kimberly RP, Brown E, Edberg J, Stevens AM, JacobCO, Tsao BP, Gilkeson GS, Kamen DL, Merrill JT, Petri M, Ramsey-Goldman R, Vila LM,Anaya J-M, Niewold TB, Martin J, Pons-Estel BA, Sabio JM, Callejas JL, Vyse TJ, Bae S-C,Perrino FW, Freedman BI, Scofield RH, Moser KL, Gaffney PM, James JA, Langefeld CD,Kaufman KM, Harley JB, Atkinson JP. Evaluation of the TREX1 gene in a large multi-ancestrallupus cohort. Genes Immunity 12:270-279, 2011. (PMCID:PMC3107387)

185. Lessard CJ, Adrianto I, Kelly JA, Kaufman KM, Grundahl KM, Adler A, Williams AH,Gallant C, Alarcón-Riquelme ME for the BIOLUPUS and GENLES Networks, Anaya J-M, BaeS-C, Boackle SA, Brown EE, Chang D-M, Criswell LA, Edberg JC, Freedman BI, GregersenPK, Gilkeson GS, Jacob CO, James JA Kamen DL, Kimberly RP, Martin J, Merrill JT, NiewoldTB, Park S-Y, Petri MA, Pons-Estel BA, Rosalind Ramsey-Goldman R, Reveille JD, Song YW,Stevens AM, Tsao BP, Vila LM, Vyse TJ, Yu C-Y, Guthridge JM, Bruner GR, Langefeld CD,Montgomery C, Harley JB, Scofield RH, Gaffney PM, Moser KL. Identification of a systemiclupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multi-ethnicstudy. Am J Hum Genet 88:83-91, 2011 (PMCID:PMC3014359)

27

186. Zhao J, Wu H, Khosravi M, Huijuan Cui H, Qian X, Kelly JA, Kaufman KM, LangefeldCD, Williams AH, Comeau ME, Julie T. Ziegler JT, Marion MC, Adam Adler A, Glenn SB,Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLES networks, Harley JB, Bae S-C, Lee JH, J-S Lee, Jacob CO, Timothy J. Vyse TJ, Niewold TB, Gaffney PM, Moser KL,Kimberly RP, Edberg JC, Brown EE, Petri MA, Ramsey-Goldman R, Vila LM, Reveille JD,James JA, Gilkeson, Kamen DL, Freedman BI, Anaya J-M, Merrill JT, Criswell LA, ScofieldRH, Stevens AM, Boackle SA, Guthridge JM, Chang D-M, Song YW, Grossman JM, Hahn BH,Goodship THJ, Cantor RM, Yu C-Y, Shen N, Tsao BP. Association of Genetic Variants inComplement Factor H and Factor H-Related Genes with Systemic Lupus ErythematosusSusceptibility. PloS Genetics 7:e1002079, 2011 (PMCID:PMC3102741)

187. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA,Kaufman KM, Guthridge JM, Alarcon-Riquelme ME for the BIOLUPUS and GENLESNetworks, Anaya JM, Bae SC, Bang SY, Boackle SA, Brown EE, Petri MA, Gallant C,Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, GregersenPK, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, NiewoldTB, Park SY, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD,Harley JB, Moser KL, Webb CF, Humphrey MB, Montgomery CG, Gaffney PM. Association ofa functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nature Genet43:253-258, 2011. (PMCID:PMC3103780)

188. Scofield RH. Vasculitis in Sjögren's Syndrome. Curr Rheumatol Rep 13:482-488, 2011(No PMCID required)

189 Scofield RH. Can Genetic Changes Predict Manifestations of SLE. Viewpoints in GenomicMedicine, in Medscape Genomic Medicine, May 2011 (No PMCID required)(http://www.medscape.com/viewarticle/742165)

190. Kurien BT, Porter A, Dorri Y, Iqbal S, D'Souza A, Singh A, Asfa S, Cartellieri M, MathiasK, Matsumoto H, Bachmann M, Hensley K, Scofield RH. Degree of modification of Ro60 by thelipid peroxidation by-product 4-hydroxy-2-nonenal differentially induces Sjogren's syndrome orsystemic lupus erythematosus in BALB/c mice. Free Radical Biol Med 50:1222-1233, 2011(PMCID:PMC3591494).

191. Scofield RH. IL-21 and Sjögren’s syndrome. Arthritis Res Ther 13:137, 2011 (PMCID:PMC3334639)

192. Tan W, Sunahori K, Zhao J, Deng Y, Kaufman KM, Kelly JA, Bae S-C, Lee JH, Lee J-S,Chang D-M, Song YW, Yu C-Y, Robert P. Kimberly RP, Edberg JC, Brown EE, Petri MA,Ramsey-Goldman R, Vila LM, Reveille JD, Alarcón-Riquelme ME on behalf of the BIOLUPUSand GENLES networks, Harley JB, Boackle SA, Stevens AM, Scofield RH, Merrill JT,Freedman BI, Anaya, J-M, Criswell LA, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, MoserKL, Gilkeson GS, Kamen DL, James JA, Grossman JM, Hahn BH, Tsokos GC, Tsao BP.

28

Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups. Arthritis Rheum 63:2755-2763, 2011(PMCID: PMC3163110)

193. Namjou B, Choi C-B, Isaac T. W. Harley ITW, Kim K, Kelly JA, Glenn SB, Ojwang JO,Adler A, Alarcón-Riquelme ME, Caroline J. Gallant CJ, Susan A. Boackle SA, Criswell LA,Kimberly RP, Brown E, Edberg J, Stevens AM, Jacob CO, Gilkeson GS, Kamen DL, Tsao BP,Anaya JM, Kim E-M, Guthridge J, Merrill JT, Petri M, Ramsey-Goldman R, Vila L, NiewoldTB, Martin J, Pons-Estel BA, Vyse TJ, Freedman BI, Moser KL, Gaffney PM, Williams AComeau, Reveille JD, Kang C, James JA, Scofield RH, Langefeld CD, Kaufman KM, Harley JB,Bae S-C. Evaluation of TRAF6 in a large multi-ancestral lupus cohort. Arthritis Rheum64:1960-1969, 2012, Jun. (PMCID:PMC3380425)

194. Kurien BT, D’Souza, A, Terzyan S, Scofield RH. Putative sequences on Ro60 three-dimensional structure accessible for 4-hydroxy-2-nonenal (HNE) modification compared to invitro HNE modification of Ro60 sequences. Mol Immunol 50:185-192, 2012, Feb (No PMCIDrequired)

195. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, Guthridge JM, Freedman BI,Anaya J-M, Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLES Networks, MartinJ, Glenn S, Adler A, Bae S-C, Park S-Y, Boackle SA, Brown EB, Edberg JC, Alarcón GS, PetriM, Criswell LA, Ramsey-Goldman R, Reveille JD, Vila LM, Gilkeson GS, Kamen DL, Ziegler J,Jacob CO, Rasmussen A, James JA, Kimberly RP, Merrill JT, Niewold, TB, Scofield RH,Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Moser KL, Harley JB, Gaffney PM,Montgomery CG. Role of MYH9 and APOL1 in African and non-African populations with LupusNephritis. Gene Immunity 13:232-238, 2012, Apr. (PMCID:PMC3330160

196. Scofield RH, Kaufman KM. Mapping Susceptibility Gene in Systemic LupusErythematosus. In, Perl A, ed, Autoimmunity: Methods and Protocols, Methods in MolecularBiology 900:11-15, 2012 (No PMCID required)

197. Lessard CJ, Ice JA, Maier-Moore S, Montgomery CG, Scofield RH, Kathy L. Moser KL.Genetics, Genomics, and Proteomics of Sjögren’s syndrome. In, Ramos-Casals M, Stone JH,Moutsopoulos HM, eds, Sjögren’s Syndrome: Diagnosis and Therapeutics, 11-32, 2012. (NoPMCID required)

198. Dillon SP, Kurien BT, Li S, Bruner GR, Kaufman KM, Harley JB, Gaffney PM, WallaceDJ, Weisman MH, Scofield RH. Sex chromosome Aneuploides among Men with SystemicLupus Erythematosus, J Autoimmun 38:J129-J134, 2012, May. Epub ahead of print 5 Dec 2011(PMCID:PMC3309073)

199. Scofield AK, Radfar L, Ice J, Houston GD, Lewis D, Moser KL, Scofield RH. PeripheralNeuropathy in Sjögren’s Syndrome. J Clin Rheumatol 18:290-293, 2012, Sep.(PMCID:PMC3577358)

29

200. Wang S, Adrianto I, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH,Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM,Alarón-Riquelme ME on behalf of the BIOLUPUS and GENLES Networks, Alarcón GS, AnayaJ-M, Bae S-C, Kim J-H, Joo YB, Boackle SA, Brown EE, Petri MA, Ramsey-Goldman R,Reveille JD, Vilá LM, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, JamesJA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH,Stevens AM, Tsao BP, Vyse TJ, Langefeld CD,Harley JB, Wakeland EK, Moser KL,Montgomery, CG, Gaffney PM. A functional haplotype of UBE2L3 confers risk for Systemic 1Lupus Erythematosus. Genes Immun 13:380-3807, 2012, Jul. Epub 2012 Apr 5.(PMCID:PMC3411915)

201. Sawalha AH. Wang L, Nadig A, Somers E, McCune J on behalf of the Michigan LupusGroup, Hughes T, Merrill J, Scofield RH, Strickland. F. Richardson B. Gender-specificdifferences in the relationship between genetic susceptibility, T cell DNA demethylation andlupus flare severity. J Autoimmun 38:J216-222, 2012 May. Epub 2012 Feb 3.(PMCID:PMC3313010)

202. Hughes T, Adler A, Merrill JT, Kelly JA, Kaufman KM, Williams A, Langefeld CD,Gilkeson GS, Sanchez E, Martin J, Boackle SA, Stevens AM, Alarcón GS, Niewold TB, BrownEE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Criswell LA, Vilá LM,Jacob CO, Gaffney PM, Moser KL, Vyse TJ, Alarcón-Riquelme ME; BIOLUPUS Network,James JA, Tsao BP, Scofield RH, Harley JB, Richardson BC, Sawalha AH. Analysis ofautosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemiclupus erythematosus. Ann Rheum Dis 71:694-699, 2012 May. Epublished ahead of print 2011Nov 21. (PMCID:PMC3324666)

203. Scofield RH. Viewpoints in Genetic Medicine: Shared Genetics between Lupus and OtherAutoimmune disease. In, Beuhler B, ed. Medscape Genomic Medicine, 2012 (No PMCIDrequired)

204. Kaufman KM, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD,Ziegler JT, Williams AH, Comeau ME, Marion MC, Glenn SB, James JA, Guthridge, J,Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Brown EB, Vilá LM,Anaya J-M, Boackle SA, Stevens AM, Freedman BI, Criswell LA, Jacob CO, Scofield RH,Gilkeson GS, Moser KL, Gaffney PM, Merrill JT, Niewold TB, Vyse TJ, Bae, S-C, Alarcón-Riquelme ME on behalf of the BIOLUPUS network, Harley JB, Sawalha AH, Betty P. Tsao BP.Fine mapping of Xq28: Both MECP2/IRAK1 and NAA10/RENBP contribute to risk forsystemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis 72:437-444, 2013Mar (PMCID:PMC3567234)

205. Hughes T, Adler A, Kelly JA, Kaufman KM, Williams AH, Langefeld CD, Brown EE,Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Boackle SA, Stevens AM,

30

Reveille JD, Sanchez E, Martín J, Niewold TB, Vilá LM, Scofield RH, Gilkeson GS, GaffneyPM, Criswell LA, Moser KL, Merrill JT, Jacob CO, Tsao BP, James JA, Vyse TJ,Alarcón-Riquelme ME; BIOLUPUS Network, Harley JB, Richardson BC, Sawalha AH.Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupuserythematosus. Arthritis Rheum 64:485-492, 2012 Feb. (PMCID:PMC3268866)

206. Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, Adler AJ, Li H, RasmussenA, Williams AH, Ramos PS, Grundahl KM, Gallant CJ, Alarcón-Riquelme ME for theBIOLUPUS and GENLES Networks, Alarcon GS, Anaya J-M, Bae S-C, Boackle SA, Brown EE,Chang D-M, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, KamenDL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Park S-Y, Petri MA, Pons-Estel BA,Ramsey-Goldman R, Reveille JD, Scofield RH, Song YW, Stevens AM, Tsao BP, Vila LM,Vyse TJ, Yu C-Y, Guthridge JM, Kaufman KM, Harley JB, Wakeland EK, Langefeld CD,Gaffney PM, Montgomery CG, Moser KL. Identification of IRF8, TMEM39A, AND IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale, multi-racialreplication study. Am J Hum Genet 90:648-660, 2012 Apr (PMCID:PMC3322228)

207. Kim K, Brown EE, Choi C-B, Alarcón-Riquelme ME on behalf of BIOLUPUS, Kelly JA,Glenn SB, Ojwang JO, Adler A, Bang S-Y, Lee H-S, Boackle SA, Criswell LA, Kim T, AlarconGS, Edberg JC, Stevens AM, Jacob CO, Gilkeson GS, Kamen DL, Tsao BP, Anaya J-M,Guthridge JM, Nath SK, Richardson B, Sawalha AH, Kang YM, Shim SC, Suh C-H, Lee S-K,Kim C-S, Merrill JT, Petri M, Ramsey-Goldman R Vilá LM, Niewold TB, Martin J, Pons-EstelBA on behalf of GENLES, Vyse TJ, Freedman BI, Moser KL Gaffney PM, Williams A, ComeauM, Reveille JD, James JA, Scofield RH, Langefeld, CD, Kaufman KM, Harley JB, Kang C,Kimberly RP, Bae S-C. Variation in the ICAM1-ICAM4-ICAM5 locus is associated withsystemic lupus erythematosus susceptibility in multiple ancestry populations. Ann Rheum Dis71:1809-1814, 2012 Nov (PMCID:PMC3466387)

208. Namjou B, Keddache M, Fletcher D, Dillon S, Kottyan L, Wiley G , Gaffney PM,Wakeland BE, Liang C, Wakeland EK, Scofield RH, Kaufman KM, Harley JB. Identification ofnovel coding mutation in C1qA gene in an African-American pedigree with lupus and C1qdeficiency. Lupus 21:1113-1118, 2012, Sep. Epub 2012 Apr 3. (PMCID:PMC3508769)

209. Lu R, Robertson J, Bruner B, Guthridge JM, Neas B, Nath SK, Kelly JA, Moser KL,Chakravarty E, Kamen D, Gilkeson GS, Scofield RH, Harley JB, James JA. Multipleautoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large,ethnically diverse SLE patient cohort. Autoimmune Dis 2012:819634, 2012. Epub 2012 Sep 4.(PMCID:PMC3439936)

210. Gaddy JR, Khan ZZ, Chaser B, Scofield RH. Whipple's disease diagnosis following theuse of TNF-á blockade. Rheumatol (Oxford) 51:946, 2012, May (No PMCID required)

211. Sánchez E, Rasmussen A, Riba L, Acevedo E, Kelly JA, Langefeld CD, Williams AH,

31

Ziegler JT, Comeau ME, Marion MC, IGarcía-De La Torre I, Maradiaga-Ceceña MA, Cardiel MH, Esquivel-Valerio JA, Rodriguez-Amado J, Moctezuma JF, Miranda P, Perandones C,Castel C, Laborde HA, Alba P, Musuruana J, Goecke A, Foster C, Anaya JM, Kaufman KM,Adler AJ, Glenn SB, Brown EE, Alarcón GS, Kimberly RP, Edberg JC, Vilá LM, Criswell LA,Gilkeson GS, Niewold TB, Martin J, Vyse TJ, Boackle SA, Ramsey-Goldman R, Stevens AM,Scofield RH, Petri M, Merrill JT, Reveille JD, Tsao BP, Orozco L, Baca V, Moser KL, GaffneyPM, James JA, Harley JB, Tusié-Luna T, Pons-Estel BA, Jacob CO, Alarcón-Riquelme ME.Impact of Genetic Ancestry and Socio-Demographic Status on the Clinical Expression ofSystemic Lupus Erythematosus in Amerindian-European Populations, Arthritis Rheum64:3687-3694, 2012, Nov (PMCID:PMC3485439)

212. Adrianto I, Wang S, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH,Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM,Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC,Kim JH, Joo YB, Boackle SA, Brown EE, Petri MA, Ramsey-Goldman R, Reveille JD, Vilá LM,Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, KimberlyRP, Martín J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, VyseTJ, Langefeld CD, Harley JB, Wakeland EK, Moser KL, Montgomery CG, Gaffney PM.Association of two independent functional risk haplotypes in TNIP1 with systemic lupuserythematosus. Arthritis Rheum 64:3695-3705, Nov 2012 PMCID:PMC3485412)

213. Bruner BF, Gutherridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, Kamen DL, GilkesonGS, Neas BR, Reichlin M, Scofield RH, Harley JB, James JA. Comparison of autoantibodyspecificities and clustering between traditional and bead-based autoantibody assays in a large,ethnically diverse collection of SLE patients and family members. Arthritis Rheum 64:3677-3686, Nov 2012 (PMCID:PMC3490432)

214. Kurien BT, Dorri Y, Bachmann M, Scofield, RH. Induction of anti-Ro60/anti-La byimmunization with spectrin and, induction of anti-spectrin by immunization with Ro60 and 4-hydroxy-2-nonenal-modified Ro60 immunization. Clin Exp Rheumatol 30:886-893, Nov-Dec2012.

215. Kurien BT, Scofield RH, eds. Protein electrophoresis: Methods and Protocols (HumanaPress: New York), 2012 (No PMCID required)

216. Kurien BT, Mohan C, Scofield RH. Mechanisms of Tissue Damage - Free radicals andfibrosis, In, Wallace DJ, Hahn BH, eds, Dubois’ Lupus Erythematosus and RelatedSyndromes (Elsevier:Philadelphia), pp 175-190, 2013 (No PMCID required)

217. Radfar L, Scofield RH. Kikuchi-Fujimoto Disease in Patients with Sjögren’s Syndrome.Open J Pathol 3:32-36, 2013 (PMCID:PMC3577358)

218. Aggarwal R, Dillon SP, Sestak AL, Chakravarty EF, Harley JB, Scofield JB. Excess female

32

siblings and male fetal loss in lupus families. J Rheumatol 40:430-434, 2013 Apr(PMCID:PMC3693848)

219. Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Langefeld CD, Kelly JA,Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Brown EE, Petri M, Ramsey-Goldman R, Reveille JD, James JA, Guthridge J, Merill JT, Boackle SA, Freedamn BI, ScofieldRH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Segovia ME, Harley JB, GilkesonGS. Association of reactive intermediate genes with systemic lupus erythematosus (SLE) variesacross populations with different African ancestries. J Rheumatol 40:842-849, 2013 Jun(PMCID:PMC3735344)

220. Molineros JE, Maiti AK, Sun C, Looger LL, Kim-Howard X, Glenn S, Adler A, Han S,Kelly JA, Niewold TB, Gilkeson GS, Brown EE, Graciela S. Alarcón GS, Edberg JC, Petri M,Ramsey-Goldman R, Reveille JD, Vilá LM, Freedman BI, Tsao BP, Criswell LA, Jacob CO,Vyse TJ, Langefeld CL, Guthridge JM, Gaffney PM, Moser KL, Scofield RH, Alarcón-RiquelmeME on behalf of the BIOLUPUS Network, Williams SM, Merrill JT, James JA, Kenneth M.Kaufman KM, Kimberly RP, Harley JB, Nath SK. Admixture Mapping in Systemic LupusErythematosus (SLE) Identifies Multiple Common Functional Variants within IFIH1 Associatedwith Apoptosis, Inflammation and Autoantibody Production PloS Genetics 9(2):e1003222,2013 Feb. (PMCID:PMC3575474)

221. Deng Y, Zhao J, Sakurai D, Kaufman KM, Edberg JC, Kimberly RP, Kamen DL, GilkesonGS, Jacob CO, Scofield RH, Langefeld CD, Kelly JA, Ramsey-Goldman R, Petri MA, ReveilleJD, Vilá LM, Alarcón GS, Vyse TJ, Pons-Estel BA; Argentine Collaborative Group, FreedmanBI, Gaffney PM, Sivils KM, James JA, Gregersen PK, Anaya JM, Niewold TB, Merrill JT,Criswell LA, Stevens AM, Boackle SA, Cantor RM, Chen W, Grossman JM, Hahn BH, HarleyJB, Alarc?n-Riquelme ME; BIOLUPUS and GENLES networks, Brown EE, Tsao BP.MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated withsystemic lupus erythematosus. PLoS Genet 9(2):e1003336, 2013. (PMCID:PMC3585142)

222. Kurien BT, D’souza A, Igoe A, Le YJ, Maier-Moore J, Gordon TP, Jackson M, ScofieldRH. Immunization with 60 kD Ro peptide produces different stages of pre-clinical autoimmunityin a Sjögren’s syndrome-model among multiple strains of inbred mice. Clin Exp Immunol173:842-849, 2013 May (PMCID:PMC3694536)

223. Maier-Moore JS, Cañas CA, Tobón G, Anaya, J-M, Scofield RH. The CCR5 delta 32polymorphism (rs333) is not associated with Sjögren's syndrome or Type 1 Diabetes inColombians. Clin Immunol 148:206-208, 2013 May

224. Namjou B, Kim-Howard X, Sun C, Adler A, Chung SA, Kaufman KM, Kelly JA, GlennSB, Guthridge JM, Scofield RH, Kimberly RP, Brown EE, Alarcón GS, Edberg JC, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Boackle SA, Freedman BI, Tsao BP, LangefeldCD, Vyse TJ, Jacob CO, Niewold TB, Moser Sivils KL, Merrill JT, Anaya J-M, Gilkeson GS,

33

Gaffney PM, Bae S-C, Alarcón-Riquelme BIOLUPUS network, Harley JB, Criswell LA, JamesJA, Nath SK. PTPN22 association in systemic lupus erythematosus (SLE) with respect toindividual ancestry and clinical sub-phenotypes. PLoS One 8:e69404, 2013, Aug(PMCID:PMC3737240)

225. Scofield RH. Ro/SSA Autoantibodies. In, eds, Shoenfeld Y, Meroni PL, and Gershwin ME.The Autoantibodies (Elsevier:New York), pp 233-238, 2014 (No PMCID required)

226. Igoe A, Scofield RH. Autoimmunity and Infection in Sjogren's Syndrome. Curr OpRheumatol 25:480-487, 2013 Jul

227. Scofield RH. Genetics of Systemic Lupus Erythematosus. In, Beuhler B, ed. MedscapeReference, 2013 (No PMCID required).

228. Chaudhry MA, Scofield RH. Atypical Rocky Mountain spotted fever with polyarticulararthritis. Am J Med Sci. 346:427-429, 2013 Nov. (No PMCID required)

229. Caster D, Korte E, Nanda S, Oliver R, G’Sell R, Sheehan R, Freeman D, Coventry S, KellyJ, Guthridge J, James J, Sivils K, Alarcon-Riquelme M, Scofield RH, Adrianto I, Gaffney P,Stevens A, Freedman B, Langefeld C, Tsao B, Pons-Estel B, Jacob C, Kamen D, Gilkeson G,Brown E, Alarcon G, Edberg J, Kimberly RP, Martin J, Merrill J, Harley J, Kaufman K, ReveilleJ, Anaya JM, Criswell LA, Vila L, Petri M, Ramsey-Goldman R, Bae SC, Boackle S, Vyse T,Niewold T, McLeish K, Cohen P, Powell D. ABIN1 dysfunction as genetic basis for lupusnephritis. J Am Soc Nephrol 24:1743-1754, 2013 Nov (PMCID:PMC3810087).

230. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, Kelly JA, DozmorovMG, Miceli-Richard C, Bowman S, Lester S, Eriksson P, Elorant M-L, Brun JG, Gøransson LG,Erna Harboe E, Guthridge JM, Kaufman KM, Kvarnström M, Jazebi H, Cunninghame GrahamDS, Grandits ME, Nazmul-Hossain ANM, Patel K, Adler AJ, Maier-Moore JS, Farris AD,Brennan MT, Lessard JA, Chodosh J, Gopalakrishnan R, Hefner KS, Houston GD, Huang AJW,Hughes PJ, Lewis DM, Radfar L, Rohrer MD, Stone DU, Wren JD, Vyse TJ, Gaffney PM, JamesJA, Omdal R, Marie Wahren-Herlenius M, Illei GG, Witte T, Jonsson R, Rischmueller M,Rönnblom L, Nordmark G, Wan-Fai Ng for UK Primary Sjögren's Syndrome Registry, MarietteX, Anaya J-M, Rhodus NL, Segal BM, Scofield RH, Montgomery CG, Harley JB, Moser SivilsKL. Identification of multiple genetic variants associated with Sjögren’s syndrome involved inboth the innate and adaptive immune responses. Nature Genet 45:1284-1292, 2013 Nov(PMCID:PMC3867192)

231. Kurien BT, D’Souza A, Bruner B, Gross T, James JA, Targoff IN, Harley ITW, Wang H,Scofield RH. Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J RheumDis 16:674-680, 2013 Dec (PMCID:PMC4030668)

232. Maier-Moore JS, Koelsch KA, Smith K, Lessard CJ, Radfar L, Lewis D, Kurien BT,

34

Wolska N, Deshmukh U, Rasmussen A, Sivils KL, James JA, Farris AD, Scofield RH.Antibody-secreting cell specificity in labial salivary glands reflects clinical presentation andserology in Sjögren's syndrome patients. Arthritis Rheum 66:3445-3456, 2014 Dec(PMCID:PMC4245382)

233. Sakurai D, Zhao J, Deng, Kelly JA, Brown EE, Harley JB, Bae S-C, Marta E. Alarcün-Riquelme ME on behalf of the BIOLUPUS and GENLES networks, Edberg JC, Kimberly RP,Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Alarcón GS, Kaufman KM, Vyse TJ,Jacob CO, Gaffney PM, Moser Sivils KM, James JA, Kamen DL, Gilkeson GS, Niewold TB,Merrill JT, Scofield RH, Criswell LA, Stevens AM, Boackle SA, Freedman BI, Anaya J-M,Martin J, Yung Yu Y, Chang D-M, Song YW, Langefeld CD, Chen W, Grossman JM, CantorRM, Hahn, BH, Tsao BP. Preferential Binding to Elk-1 by SLE-Associated IL10 risk allele up-regulates IL10 expression. PLoS Genet 9:e1003879, 2013 Oct (PMCID:PMC3794920)

234. Rasmussen A, Ice JA, Li H, Grundahl K, Kelly JA, Radfar L, Stone DU, Hefner KS, AnayaJ-M, Rohrer M, Gopalakrishnan R, Houston GD, Lewis DM, Chodosh J, Harley JB, Hughes P,Maier-Moore JS, Montgomery CG, Rhodus NL, Farris AD, Segal BM, Lessard CJ, Scofield RH,Moser-Sivils KL. Comparison of the American-European Consensus Group Sjögren’s syndromeclassification criteria to newly proposed American College of Rheumatology criteria in a large,carefully characterized sicca cohort. Ann Rheum Dis 73:31-38, 2014 Jan(PMCID:PMC3855629) (epub 22 Aug 2013)

235. Altorok M, Coit P, Hughes T, Koelsch K, Scofield RH, Sivils K, Farris AD, Sawalha AH. Genome-wide DNA methylation patterns in naïve CD4+ T cells from patients with primarySjögren’s syndrome. Arthritis Rheum 66:731-9, 2014 Mar (PMCID:PMC4009982)

236. Guthridge JM, Lu, R, Sun H, Sun C, Wiley GB, Dominguez N, Macwana SR, Lessard CJ,Kim-Howard X, Cobb BL, Kaufman KM, Kelly JA, Langfield CD, Adler AJ, Harley IT, MerrillJT, Gilkeson GS, Kamen DL, Niewold TB, Brown EE, Edberg JC, Petri MA, Ramsey-GoldmanR, Reveille JD, Villa LM, Kimberly RP, Freedman BI, Stevens AM, Boackle SA, Criswell LA,Vyse TJ, Behrens, Jacob CO, Alarcón-Riquelme ME on behalf of the BIOLUPUS Network,Sivils KL, Bae S-C, Cho SK, Bang SY, Kim LL, Choi C-B, Shen N, Qian X, Tsao BP, HarleyJB, Scofield RH, Webb CF, Wakeland EK, James JA, Nath SK, Graham RR, Gaffney PM.Two functional lupus associated BLK promoter variants control cell-type and developmentalstage specific transcription. Am J Hum Genet 94:586-98; 2014 Apr (PMCID:PMC3980411)

237. Ritterhouse LL, Lu R, Shah HB, Robertson JM, Fife DA, Maecker HT, Du H, Fathman CG,Chakravarty EF, Scofield RH, Kamen DL, Guthridge JM, James JA. Vitamin D deficiency in amultiethnic healthy control cohort and altered immune response in vitamin d deficientEuropean-American healthy controls. PLoS One 9:e94500 2014 Apr (PMCID:PMC3984168)

238. Scofield RH. Rheumatic disease and the microbiome. Int J Rheum Dis 17(5):489-92, 2014Jun (PMCID:PMC4413891)

35

239. Abdul Sharief S, Scofield RH. Milk-Alkali Syndrome. Medscape Reference. UpdatedAugust 12, 2014. Available at: http://emedicine.medscape.com/article/123324-overview. (NoPMCID required)

240. Kottyan LC, Zoller EE, Bene J, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE,Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG,Hirschfield GM, Xie G, Coltescu C, Amos C, Li H, Ice JA, Nath SK, Mariette X, Bowman S; forUK Primary Sjögren's Syndrome Registry, Rischmueller M, Lester S, Brun JG, Gøransson LG,Harboe E, Omdal R, Cunninghame-Graham DS, Vyse T, Miceli-Richard C, Brennan MT,Lessard JA, Wahren-Herlenius M, Kvarnström M, Illei GG, Witte T, Jonsson R, Eriksson P,Nordmark G, Ng WF; for UK Primary Sjögren's Syndrome Registry, Anaya JM, Rhodus NL,Segal BM, Merrill JT, James JA, Guthridge JM, Scofield RH, Alarcon-Riquelme M, Bae SC,Boackle SA, Criswell LA, Gilkeson G, Kamen DL, Jacob CO, Kimberly R, Brown E, Edberg J,Alarcón GS, Reveille JD, Vilá LM, Petri M, Ramsey-Goldman R, Freedman BI, Niewold T,Stevens AM, Tsao BP, Ying J, Mayes MD, Gorlova OY, Wakeland W, Radstake T, Martin E,Martin J, Siminovitch K, Moser Sivils KL, Gaffney PM, Langefeld CD, Harley JB, KaufmanKM. The IRF5-TNPO3 association with systemic lupus erythematosus has two components thatother autoimmune disorders variably share. Hum Mol Genet 24:582-96, 2015, Jan(PMCID:PMC4275071)

241. Radfar L, Ahmadabadi RE, Masood F, Scofield RH. Biological therapy and dentistryA review paper. Oral Surg Oral Med Oral Pathol Oral Radiol 120(5):594-601, 2015 Nov

242. Clark EG, Greg Knoll G, Bugeja A, Kevin D. Burns KD, Scofield RH. Lupus AfterKidney Donation: A Case Report with Implications for the Evaluation of Potential Donors with aFamily History of Lupus. Transplantation 99:27-28, 2015 Apr

243. Maier-Moore JS, Kurien BT, D’Souza A, Bockus L, Asfa S, Dorri Y, Hubbell S, YeliosofO, Obeso D, Jonsson R, Scofield RH. Passive transfer of antibodies to the linear epitope 60 kDRo 274-290 induces features of Sjögren’s syndrome in naïve mice. Clin Exp Immunol 180:19-27, 2015 Apr (PMCID:PMC4367090)

244. Fayyaz A, Igoe A, Danda D, Kurien BT, James JA, Stafford HA, Scofield RH. Hematological manifestations of lupus. Lupus Sci Med. 3;2(1):e000078, 2015 Mar(PMCID:PMC4378375) 245. Lu X, Zoller EE, Weirauch MT, Wu Z, Namjou B, Williams AH, Ziegler JT, Comeau ME,Marion MC, Glenn SB, Adler A, Shen N, Nath SK, Stevens AM, Freedman BI, Tsao BP, JacobCO, Kamen DL, Brown EE, Gilkeson GS, Alarcón GS, Reveille JD, Anaya J-M, James JA,Moser KL, Criswell LA, Vilá LM, Alarcón-Riquelme ME, Petri M, Scofield RH, Kimberly RP,Ramsey-Goldman R, Joo YB, Choi J, Bae S-C, Boackle SA,Vyse TJ, Guthridge JM Gaffney PM,Langefeld CD, Kelly JA, Greis KD, Kaufman KM, Harley JB, Kottyan LC. Lupus risk-variant

36

increases pSTAT1 binding and decreases ETS1 expression. Am J Hum Genet 7;96:731-739,2015 May (PMCID:PMC4570281)

246. Vaughn S, Foley C, Magnusen A, Williams AH, Ziegler JT, Comeau ME, Marion MC,Glenn SB, Adler A, Frank S, Zhu ML, Shen N, Nath S, Stevens AM, Freedman BI, Tsao BP,Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcon GS, Merrill JT, Reveille JD, Anaya J-M, James JA, Moser KL, Criswell LA, Vilá LM, Alarcon-Riquelme ME, Michelle Petri M,Scofield RH, Kimberly RP, Ramsey-Goldman R, Bae S-C, Boackle SA Vyse TJ, Guthridge JM,Namjou B, Gaffney PM, Langefeld CD, Kaufman KM, Kelly JA, Harley ITW, Harley JB,Kottyan LC. Lupus risk variants in the PXK locus alter B-cell receptor internalization. FrontGenet 5:450, 2015 Jan (PMCID:PMC4288052)

247. Sandhya P, Jeyaseelan L, Scofield RH, Danda D. Clinical Characteristics and Outcome ofPrimary Sjogren's Syndrome: A Large Asian Indian Cohort. Open Rheumatol J 26:9:36-45,2015 Jun. (PMCID:PMC4493630)

248. Kurien BT, Scofield RH, eds. Western Blotting. (Humana Press:New York), 2015.

249. LaBryer L, Sawh R, McLaurin C, Scofield RH. Calcitonin-Secreting NeuroendocrineTumor of Larynx with Metastasis to Thyroid. Case Reports Endocrinol 2015:606389, 2015Sep (PMCID:PMC4600946)

250. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE,Ramos-Casals M, Dörner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, BartoloniE, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, BrunJG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A,Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T,Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, PraprotnikS, Tomsic M, Price E, Scofield H, L Sivils K, Smolen J, Laqué RS, Steinfeld S, Sutcliffe N,Sumida T, Valesini G, Valim V, Vivino FB, Vollenweider C. EULAR Sjögren's syndromedisease activity index (ESSDAI): a user guide. RMD Open 20;1(1):e000022, 2015 Feb(PMCID:PMC461315)

251. Kurien BT, Harris VM, Quadri SM, Coutinho-de Souza P, Cavett J, Moyer A, Ittiq B,Metcalf A, Ramji HF, Truong D, Kumar R, Koelsch KA, Centola M, Payne A, Danda D,Scofield RH. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria inMRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumintreatment. Lupus Sci Med 8;2(1):e000114, 2015 Sep (PMCID:PMC4567741)

252. Kurien BT, Danda D, Scofield RH. Therapeutic potential of curcumin and curcuminanalogues in rheumatology. Int J Rheum Dis 18(6):591-593, 2015 Jul

37

253. Zhao J, Wu H, Langefeld CD, Kaufman KM, Kelly JA, Bae S-C, Alarcón-Riquelme ME,Alarcon GS, Anaya J-M, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, JamesJA, Merrill JT, Gaffney PM, Moser Sivils KNiewold TB, Petri MA, Song ST, Jeong H-J,Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vila LM, Chang D-M, Song YW, Vyse TJ, Harley JB, Brown EE, Edberg JC, Kimberly RP, Hahn BH, GrossmanJM, Tsao BP. Genetic associations of leptin-related polymorphisms with systemic lupuserythematosus. Clin Immunol 161:157-162, 2015 Dec (PMCID:PMC4658308)

254. Aggarwal R, Anaya J-M, Koelsch KA, Kurien BT, Scofield RH. Association of secondaryand primary Sjögren’s in a large collection of lupus families, Autoimmune Dis 2015:298506,2015 (PMCID:PMC4515287)

255. Zhao J, Giles BM, Taylor RL, Yette GA, Lough KM, Ng HL, Abraham LJ, Wu H, KellyJA, Glenn SB, Adler AJ, Williams AH, Comeau ME, Ziegler JT, Marion M, Alarcón-RiquelmeME, Alarcón GS, Anaya JM, Bae SC, Kim D, Lee HS, Criswell LA, Freedman BI, Gilkeson GS,Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT, Sivils KM, Niewold TB, Petri MA,Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Vilá LM, Vyse TJ, Kaufman KM,Harley JB, Langefeld CD, Gaffney PM, Brown EE, Edberg JC, Kimberly RP, Ulgiati D, TsaoBP, Boackle SA; for the BIOLUPUS and GENLES Networks. Preferential association of afunctional variant in complement receptor 2 with antibodies to double-stranded DNA. AnnRheum Dis 75:242-252, 2016 Jan (PMCID:PMC4717392)

256. Wolska N, Rybakowska P, Klopocki A, Brown M, Montgomery C, Grundahl K,Rasmussen A, Scofield RH, Radfar L, Stone DU, Anaya JM, Lessard CJ, Ice JA, Lewis DM,Rhodus NL, Gopalakrishnan R, Huang AJW, Hughes PJ, Rohrer MD, Weismann MH,Venuturupalli S, Guthridge JM, James JA, Sivils KL, Bagavant H, Deshmukh US. Patients withprimary Sjögren’s syndrome patients who are positive for autoantibodies to tripartite motifcontaining proteins TRIM21 and TRIM38 show greater severity of disease. Arthritis Rheum68:724-729, 2016 Mar (PMCID:PMC4767665)

257. Kurien BT, Lane JT, Scofield RH. Getting to the true values of thyroglobulin and anti-thyroglobulin antibodies. J Clin Endocrinol Metab101(3):L38-9, 2016 Mar

258. Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L,Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S,Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg J-E, Anaya J-M,Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C,Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng W-F, Nordmark G, Magnusson-Bucher S,Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T,Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH. Klinefelter’s syndrome (47,XXY)among men with Sjögren’s syndrome. Clin Immunol 168:25-29, 2016 Apr.(PMCID:PMC4940221)

38

259. Li, K, Kurien BT, Kao L, Kaufman KM, Ice JA, Roald Omdal R, Mariette X, Witte T, IlleiGG, Rischmueller M, Nordmark G, Jonsson R, Wahren-Herlenius M, Vyse TJ, CunninghameGraham DS, Brennan MT, Rybicki BA, Ng W-F, Segal BM, Rhodus NL, Merrill JT,Montgomery CG, D’souza A, Li S, Lu X, Adler AA, Maier SM, Lessard CJ, Moser KL, GaffneyPM, Harley JB, Scofield RH. Triple X syndrome (47,XXX) increases the risk of the autoimmunediseases systemic lupus erythematosus and Sjögren's syndrome: Support for a gene-dose effectfrom the X chromosome. Arthritis Rheum 68:1290-1300, 2016 May. (PMCID:PMC4940221)

260. Joachims ML, Leehan KM, Lawrence C, Pelikan R, Moore JS, Pan Z, Rasmussen A,Radfar L, Lewis DM, Houston GD, Grundahl K, Kelly J, Lessard C, Stone DU, Hefner KS,Scofield RH, Montgomery C, Sivils KL, Thompson LF, Farris AD. Single-cell analysis ofglandular T cell receptors in Sjögren’s syndrome. J Clin Invest Insight 1:e85609, 2016 Jun(PMCID:PMC4922426)

261. Fayyaz A, Scofield RH, Kurien BT. Autoantibodies in Sjögren’s Syndrome. Rheum DisClin N Am 42:419-434, 2016 Aug (PMCID:PMC4955792)

262. Vivino FB, Carsons SE, Foulks, Daniels TE, Hammitt KM, Parke A, Brennan MT, ForstotSL, Scofield RH. New Treatment Guidelines for Sjögren’s. Rheum Dis Clin N Am 42:531-552,2016 Aug

263. Scofield RH. Sjögren’s in the 21st century. Rheum Dis Clin N Am 42:xiii, 2016 Aug

264. Szczerba BM, Kaplonek P Wolska N, Rybakowska P, Klopocki, Dey P, Rasmussen A,Hefner KS, Stone DU,Young S, Lewis DM, Radfar L, Scofield RH, Sivils KM, Bagavant H, Deshmukh US. Interaction between innate immunity and Ro52-induced antibody causesSjögren’s syndrome-like disorder in mice. Ann Rheum Dis 75:617-622, 2016 Mar(PMCID:PMC4526450)

265. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman CE, Segal B, WallaceDJ, Weisman WH, Kurien BT, Sivils KL, Scofield RH. Misdiagnosis of Sjögren’s syndrome asrheumatoid arthritis or systemic lupus erythematosus. Rheumatol 55:1195-1201, 2016 Jul

266. Sandhya P, Kurien BT, Danda D, Scofield RH. Update on the Pathogenesis of Sjögren’ssyndrome. Curr Rev Rheumatol, in press

267. Fayyaz A, Scofield RH. Iatrogenic milk-alkali syndrome in a patient recovering from acuterenal failure. J Diabetes Endocrinol, in press

268. Deng Y, Zhao J, Sakurai D, Sestak AL, Osadchiy V, Langefeld CD, Kaufman KM, KellyJA, Bae S-C, Alarcón-Riquelme ME for the BIOLUPUS and GENLES networks, Alarcón GS, Anaya J-M, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, James JA, MerrillJT, Gaffney PM, Moser Sivils K, Niewold TB, Petri MA, Rosalind Ramsey-Goldman R,

39

Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vilá LM, Chang D-M, Song YW, Vyse TJ,Harley JB, Brown EE, Edberg JC, Kimberly RP,Cantor RM, Hahn BH, Grossman JM, Tsao BP. Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclearantibody production. Ann Rheum Dis, in press (PMCID:PMC4949149)

269. Fedorowski A, Li H, Yu X, Koelsch KA, Harris VM, Liles C, Murphy TA, Quadri S,Scofield RH, Sutton R, Melander O, Kem DC. Antiadrenergic autoimmunity in posturaltachycardia syndrome. Europace, epublished 4 Oct 2016

270. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, Gottenberg JE, TheanderE, Tzioufas A, De Vita S, Ramos-Casals M, Dörner T, Quartuccio L, Ravaud P, Mariette X;EULAR Sjögren Task Force (Bartoloni E, Gerli R, Bombardieri S, Kallenberg C, Bowman SJ,Brun JG, Caporali R, Devauchelle V, Saraux A, Fauchais AL, Gottenberg JE, Hachulla E, KruizeAA, Mandl T, Theander E, Mariette X, Demoulins F, Bicêtre LK, Montecucco C, Ng WF,Praprotnik S, Tomsic M, Casals MR, Scofield H, Sivils KL, Laqué RS, Sumida T, Nishiyama S,Valesini G, Valim V, Vollenweider C). Development of the ClinESSDAI: a clinical scorewithout biological domain. A tool for biological studies. Ann Rheum Dis 75(11):1945-1950,2016 Nov

271. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT,Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S, Alexander E.Treatment Guidelines for Rheumatologic and Systemic Manifestations of Sjögren’s : Use ofBiologics, Management of Fatigue and Inflammatory Musculoskeletal Pain. Arthritis Care ResJul 7. doi: 10.1002/acr.22968. [Epub ahead of print]

272. 284. Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, Li X,Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Kruize AA,Valim V, Kvarnstrom M, Sene D, Gerli R, Praprotnik S, Isenberg D, Solans R, Rischmueller M,Kwok SK, Nordmark G, Suzuki Y, Giacomelli R, Devauchelle-Pensec V, Bombardieri M,Hofauer B, Bootsma H, Brun JG, Fraile G, Carsons SE, Gheita TA, Morel J, Vollenveider C,Atzeni F, Retamozo S, Horvath IF, Sivils K, Mandl T, Sandhya P, De Vita S, Sanchez-GuerreroJ, van der Heijden E, Trevisani VF, Wahren-Herlenius M, Mariette X, Ramos-Casals M;EULAR-SS Task Force Big Data Consortium (Morcillo C, Brito-Zerón P, García-Sánchez I,Gheitasi H, Bové A, Ramos-Casals M, Horvath IF, Sivils K, Scofield H, Mariette X, Mandl T, LiX, Sandhya P, Corazza L, De Vita S, Sánchez-Guerrero J, van der Heijden E, Wahren-HerleniusM, Bartoloni E, Downie-Doyle S, Park SH, Kawano M, Carubbi F, Saraux A, Astorri E, VissinkA, Hammenfors D, Khalil HM, Morel J, Vollenveider C, Atzeni F, Retamozo S, Trevisano VM,Kostov B, Sisó-Almirall A, Sibilia J, Miceli-Richard C, Nocturne G, Benessiano J, Dieude P,Dubost JJ, Fauchais AL, Goeb V, Hachulla E, Larroche C, Le Guern V, Puéchal X, Morel J,Perdriger A, Rist S, Vittecoq O, Ravaud P, Díaz-López B, Casanovas A, Pallarés L, López-DuplaM, Pérez-Alvarez R, Ripoll M, Pinilla B, Akasbi M, Maure B, Fonseca E, Canora J, de la Red G,Chamorro AJ, Jiménez-Heredia I, Fanlo P, Guisado-Vasco P, Zamora M). Influence ofgeolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at

40

diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren ProjectConsortium. Ann Rheum Dis 2016 Nov 29 epublished ahead of print

273. Danda D, Troung D, Koelsch KA, Kurien BT, Bagavant H, Deshmukh U, Kaufman CE,Lewis D, Stone DU, Radfar L, Rasmussen A, Sivils K, Scofield RH. Anti-La positive, anti-Ronegative subset of primary Sjögren’s syndrome: Anti-La is a reality but is the disease? Clin ExpRheumatol, in press

274. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, RasmussenA, Scofield, RH, Vitali C, Bowman SJ, Mariette X and the International Working Group on SSClassification Criteria 2015 Classification Criteria for Sjögren’s Syndrome: A Consensus andData-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rhematol,in press

275. Talsania M, Hal Scofield RH. Menopause and rheumatic disease. Rheum Dis Clin N Am,in press

276. Kurien BT, Fesmire J, Scofield RH. Anti-oxidized LDL/anti-phospholipid antibodies inlupus subsets and induction of these antibodies in Ro 60/Ro60 peptide immunized animal modelof lupus. J Clin Rheumatol, in press

277. Brown MA, Fife D, Dumancas G, Bello G, Adrianto I, Rasmussen A, Grundahl KM, GlennSB, Ice JA, Kelly JA, Rhodus NL, Segal BM, Lessard CJ, Scofield RH, Sivils KL, MontgomeryCG. Novel Approaches for Examining the Predictive Validity of Screening Tools in ClinicalResearch: An Example from Sjogren's Syndrome. BMC Medical Informatics and DecisionMaking, submitted.

278. Zhao J, Giles BM, Mason R, Yette GA, Lough KM, Abraham LJ, Kelly JA, Glenn SB,Adler AJ, Williams AH, Comeau MC, Ziegler JT, Marion MC, Alarcón-Riquelme ME for theBIOLUPUS¶ and GENLES¶ Networks, Alarcón GS, Anaya J-M, Bae S-C, Brown EE, CriswellLA, Freedman BI, Gilkeson GS, Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT,Moser Sivils KM, Niewold TB, Petri MA, Ramsey-Goldman R, Reveille JD, Scofield RH,Stevens AM, Vilá LM, Vyse TJ, Kaufman KM, Harley JB, Langefeld CD, Gaffney PM, EdbergJC, Kimberly RP, Ulgiati D, Tsao BP, Boackle SA. Intronic CR2 Polymorphism Associated withSystemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression, in preparation

279. Edberg JC, Duarte C, Patki A, Comeau ME, Santago P, Brown EE, Kaufman KM, KellyJA, Adler A, Alarcón GS, Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLESnetworks, Anaya J-M, Bae S-C, Boackle SA, Criswell L, Freedman BI, Gaffney PM, GilkesonGS, Glen S, Guthridge JM, Jacob CO, James JA, Kamen DL, Marion M, Javier Martin J, MerrillJT, Niewold TB, Petri M, Pons-Estel BA, Ramsey-Goldman R, Reveille JD, Scofield RH, MoserSivils K, Stevens AM, Tsao BP, Vila LM, Vyse TJ, Williams A, Zeigler J, Harley JB, LangefeldCD, Tiwari H, Kimberly RP. Genetic Interactions Between SNP Variants in Genes Regulating

41

Complement Component 3 Activation and Recognition in Patients with SLE, in preparation

280. Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS,Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH,Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg J-E, Anaya, J-M,Cunninghame-Graham DS, Huang AJW, Brennan, MT, Hughes P, Alevizos I, Miceli-Richard C,Keystone EC, Bykerk VP, Hirschfield G, Xie G, Nordmark G, Bucher SM, Eriksson P,Omdal R,Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ,Harley JB, Sivils KL, Ng W-F, Astrid Rasmussen A, Scofield RH. Rare X chromosomeabnormalities in systemic lupus erythematosus and Sjögren’s syndrome. Arthritis Rheumtol,revisions requested

281. Scofield RH, Sharma R, Bruner GR, Cooney CM, Aberle T, Chakravarty EF, Harley JB,Rasmussen A. Impact of Ethnicity on Family Participation in SLE Genetic Studies, submitted

282. LaBryer L, Sharma R, Chaudhari KS, Talsania M, Hal Scofield RH. Kratom, an emergingdrug of abuse, raises prolactin and causes secondary hypogonadism, submitted

283. Leehan KM, Pezant NP, Rasmussen A, Grundahl K, Moore JS, Radfar L, Lewis DM,Houston GD, Stone DU, Lessard CJ, Rhodus NL, Segal BM, Scofield RH Sivils KL,Montgomery C, Farris AD. Minor salivary gland fibrosis in Sjögren’s syndrome is elevated,associated with focus score and not solely a consequence of aging, submitted

284. Stone DU, Fife D, Brown M, Earley KE, Radfar L, Kaufman CE, Lewis DM, Rhodus NL,Segal BM, Wallace DJ, Weisman, Venuturupalli S, Brennan MT, Lessard CJ, Montgomery CG,Scofield RH, Sivils KL, Rasmussen A. Effect of Tobacco Smoking on the Clinical,Histopathoilogical, and Serologial Manifestations of Sjögren’s Syndrome. PLoS One, revisionsrequested

42

Abstracts

1. Lopez, E, Scofield, RH. Tularemia pneumonia in Oklahoma. Clin. Res. 37:38A, 1989.

2. Dickey, WD, Scofield, RH, Harley. Human autoantibody production in the severe combinedimmunodeficiency (SCID) mouse. Clin. Res. 38:407A, 1990.†

3. Scofield, RH, Dickey, WD, Jackson, KW, Harley, JB. Localization of a small sequentialautoepitope near the carboxyl terminus of the 60 kD Ro/SSA in systemic lupus erythematosus.Clin. Res. 38:238A, 1990.†

4. Scofield, RH, Harley, JB. The autoantigenicity of human 60 kD Ro/SSA is related tohomologies between Ro/SSA and the nucleocapsid protein of vesicular stomatitis virus. Clin.Res. 38:316A, 1990.†

5. Scofield, RH, Dickey, WD, Jackson, KW, Harley, JB. The autoepitopes of the carboxylterminus of human 60 kD Ro/SSA in systemic lupus erythematosus. FASEB J. 4:A2103, 1990.*

6. Dickey, WD, Scofield, RH, Tateya, D, Harley, JB. Human autoantibody xenographs in severecombined immunodeficiency (SCID) mice. FASEB J. 4:A2102, 1990.*

7. Horsfall, AC, Scofield, RH, Farris, AD, Harley, JB. Sequential epitopes of anti-La/SSBautoantibodies. FASEB J. 4:A1703, 1990.*

8. Horsfall, AC, Farris, AD, Scofield, RH, Harley, JB. Sequential epitopes of anti-La/SSB incomplete congenital heart block. Arthritis Rheum. 33:S50, 1990.‡

9. Scofield, RH, Harley, JB. 60 kD Ro/SSA autoepitopes are found in regions of homologybetween Ro/SSA and the nucleocapsid protein of vesicular stomatitis virus. Arthritis Rheum.33:S101, 1990.‡

10. Scofield, RH, Dickey, WD, Hardgrave, KL, James, JA, Harley, JB. Binding to an epitope of60 kD Ro/SSA in systemic lupus erythematosus. Clin. Res. 39:311A, 1991.†

11. James, JA, Scofield, RH, Harley, JB. Sequential epitopes of human Sm autoantigen. FASEBJ. 5:A642, 1991.*

12. Scofield, RH, Warren, WL, Koelsch, G, Harley, JB. Multiple short sequence identities definea unique relationship between HLA B2705 and Klebsiella pneumoniae nitrogenase. ArthritisRheum. 34:S196, 1991.‡

13. Scofield, RH, Hardgrave, KL, Frank, MB, Harley, JB. Human autoimmune response to anepitope of 60 kD Ro/SSA. Arthritis Rheum. 34:S51, 1991.‡

43

14. Scofield, RH, Astley, GD, Dickey, WD, Harley, JB. Evaluation of the clonotypic response to60 kD Ro/SSA by affinity isoelectric focusing. Arthritis Rheum. 34:S102, 1991.‡

15. Scofield, RH, Warren, WL, Koelsch, G, Harley, JB. Convergent Evolution of HLA-B27 andEnteric Bacteria: Potentially Relevant to Spondyloarthropathies. Clin. Res. 40:260A, 1992.‡

16. Scofield, RH, Hardgrave, KL, Frank, MB, Neas, B, Harley, JB. Serologic and ImmunogeneticRelationships of Anti-Ro/SSA Titer in Systemic Lupus Erythematosus. Clin. Res. 40:360A,1992.†

17. James, JA, Scofield, RH, Harley, JB. Epitope Mapping of the 70 kD nRNP AssociatedProtein. Clin. Res. 40:434A, 1992.†

18. James, JA, Scofield, RH, Harley, JB. Charged Amino Acids Predominate in theAutoantigenic Determinates of the 70 kD Peptide Associated with the U1 Ribonuclear Particle.Arthritis Rheum. 35:S39, 1992.‡

19. Huang, SC, Hua, Y, Barber, BD, Scofield, RH, Harley, JB. Linear Epitopes of Ro. ArthritisRheum. 35:S171, 1992.‡

20. Huang, SC, Gross, T, Hua, Y, Scofield, RH, Harley, JB. Conformational Epitopes ofAutoantigen Ro/SS-A. Arthritis Rheum. 35:S62, 1992.‡

21. Hardgrave, KL, Neas, B, Scofield, RH, Harley, JB. Antibodies Binding Vesicular StomatitisVirus Proteins in Systemic Lupus Erythematosus and Normals. Arthritis Rheum. 35:S112,1992.‡

22. Scofield, RH, Dickey, WD, Harley, JB. Autoantibody Production in scid-SLE Chimeric MiceCan Be Stimulated by Recombinant IL-6 or Purified Autoantigen. Arthritis Rheum. 35:S50,1992.‡

23. Karsh, J, Scofield, RH, Harley, JB. Ro Reactive T cells in systemic Lupus Erythematosus.Arthritis Rheum. 36:R34, 1993.‡

24. Scofield, RH, Warren WL, Harley, JB. A nine amino acid peptide from the thirdhypervariable region of B27 is bound by B27 as are peptides from non-E. coli enteric bacteriathat share sequence with this region of B27. Arthritis Rheum. 36:S73, 1993.‡

25. Scofield, RH, Craven, P, Reichlin, M. Multiple dot antinuclear antibody in patients withoutprimary biliary cirrhosis. Arthritis Rheum. 36:S149, 1993.‡

26. Huang, SC, Pan, Z, Harley, JB, Scofield, RH. Immunization with vesicular stomatitis virusnucleocapsid protein induces autoantibodies to 60 kD Ro. Clin. Res. 42:278A, 1994.†

44

27. Zhang, F-C, Kurien, BT, Harley, JB, Scofield, RH. Development of the humoralautoantibody response to 60 kD Ro in patients with systemic lupus erythematosus. ArthritisRheum. 37:S172, 1994.‡

28. Kurien, BT, Harley, JB, Scofield, RH. A peptide from shigella toxin A that imitates HLA-B27 is bound by HLA-B27 as is a homologous peptide from E. coli shiga-like toxin. ArthritisRheum. 37:S203, 1994.‡

29. Scofield, RH, Huang, SC, Pan, Z, Harley, JB. Induction of anti-Ro (SS-A) by immunizationwith viral nucleocapsid protein. Arthritis Rheum. 37:S172, 1994.‡

30. Scofield, RH, Kurien, BT, James, JA, Harley, JB. Immunization with short peptides from the60 kD Ro sequence results in autoimmunity directed towards the Ro ribonucleoprotein complex.Arthritis Rheum. 37:S212, 1994.‡

31. James, JA, Gross, T, Scofield, RH, Harley, JB. Octapeptide immunized mice develop anti-spiceosomal autoantibodies. Arthritis Rheum. 37:S292, 1994.‡

32. James, JA, Gross, T, Scofield, RH, Harley, JB. Lupus humoral autoimmunity and systemicdisease induced by short peptide immunization. Arthritis Rheum. 37:S292, 1994.‡

33. James, JA, Gross, T, Scofield, RH, Harley, JB. Systemic lupus induced by short peptideimmunization. Lupus 4:2S48, 1995. (Presented at the Fourth International Lupus Meeting,Jerusalem, Israel)

34. Scofield, RH, Baker MZ. Educational needs in internal medicine residency of generalistsversus subspecialists: Results of a survey. J Gen Intern Med. 10:S93, 1995. (Presented at theSociety of General Internal Medicine national meeting)

35. Scofield, RH, Henry, WH, Kurien, BT, James, JA, Harley, JB. Induction of Ro and Laautoimmunity by immunization with peptides from 60 kD Ro. J Invest Med. 43:2S284, 1995.†

36. Kurien, BT, Moore, KL, Scofield, RH. Anti-Ro/SSA mediates granulocytopenia in systemiclupus erythematosus. J Invest Med 44:222A, 1996.†

37. Scofield, RH, Moser, KL, Kendrick, DT, Bruner GR, Avery, TA, II, Neas, BR, Harley, JB.Genetic effects for the manifestations of systemic lupus erythematosus: a study of 30 multiplexfamilies. J Invest Med 44:254A, 1996.†

38. Scofield, RH, Zhang, F-C, Kurien, BT, Harley, JB. Anti-Ro fine specificity defined bymultiple antigenic peptides reveals the components of tertiary epitopes. J Invest Med 44:298A,1996.†

45

39. Scofield, RH, Glass, GD, Neas, BR, Harley, JB. Ankylosing spondylitis is genetically linkedto HLA-B by multiple alleles which influence disease risk. Arthritis Rheum 39:S121, 1996.‡

40. Kurien, BT, Mehta, P, Gross, T, Harley, JB, Scofield, RH. Intramolecular interactions of 60kD Ro/SSA. Arthritis Rheum 39:S181, 1996.‡

41. Kurien, BT, Mehta, P, Kaufman, KM, Gross, T, Gordon, T, Harley, JB, Scofield, RH.Protein-protein interaction between Ro 60 and La polypeptides using plasmon surface resonance.Arthritis Rheum 39:S181, 1996.‡

42. Kurien, BT, Moore, KL, Scofield, RH. Granulocytopenia in systemic lupus erythematosus isrelated to anti-Ro. Arthritis Rheum 39:S181, 1996.‡

43. Scofield, RH, Zhang, F-C, Kurien, BT, Harley, JB. 60 kD Ro/SSA multiple antigenicpeptides reveal tertiary epitopes. Arthritis Rheum 39:S182, 1996.‡

44. Kaufman, KM, Gross, JK, Yu, DTY, Harley, JB, Scofield, RH. In vivo binding of gram-negative bacterial peptides to HLA-B27: a possible relationship to ankylosing spondylitispathogenesis. Arthritis Rheum 39:S298, 1996.‡

45. Farris, AD, Harley, JB, Reynolds, P, James, JA, Scofield, RH, McCluskey, J, Gordon TP.Induction of autoimmunity by multivalent immunodominant T cell determinates of La (SS-B).Arthritis Rheum 39:S315, 1996.‡

46. Scofield, RH, Glass, DN, Harley, JB. An allele frequency analysis of HLA-B in families withankylosing spondylitis. Arthritis Rheum 40:S227, 1997.‡

47. Scofield, RH, Chambers, TL, Barber, BD, Kurien, BT. Autoantibody to the leucine zipperregion of 52 kD Ro/SSA binds native 60 kD Ro/SSA: Identification of the components of thetertiary epitope in 60 kD Ro/SSA. Arthritis Rheum 40:S204, 1997.‡

48. Ford, AL, Kurien, BT, Harley, JB, Scofield, RH. Analysis of development of anti-centromereautoantibody in a patient evolving from a lupus/Sjögren's overlap to the CREST syndrome.Arthritis Rheum 40:S84, 1997.‡

49. Scofield, RH, Kurien, BT, Kaufman, KM, Baber, U, James, JA, Harley, JB. Immunization ofmice with human 60 kD Ro peptides results in epitope spreading if the peptides are highlyhomologous between man and mouse. Arthritis Rheum 41:S177, 1998.*

50. Kurien, BT, Newland, J, Paczkowski, C, Moore, KL, Scofield, RH. Association ofneutropenia in systemic lupus erythematosus with anti-Ro and binding an immunologicallycrossreactive neutrophils membrane antigen. Arthritis Rheum 41:S70, 1998.*

46

51. Kurien, BT, Scofield, RH. Antibodies to free radical scavengers and free radical damage insystemic lupus erythematosus. Arthritis Rheum 42:S309, 1999‡

52. Obeso, D, Lopéz de Castro, JA, Scofield, RH. TAP-independent recognition of HLA-B27 bycytotoxic T cells. Arthritis Rheum 42:S377, 1999 ‡

53. Kurien BT, Scofield RH. Induction of antibodies to CuZn superoxide dismutase and oxidizedLDL in 60 kD Ro immunized rabbits. Arthritis Rheum 43:S115, 2000 ‡

54. Scofield AN, Kurien BT, Gordon TP, Scofield RH. Can B cell epitopes of 60 kD Rodistinguish systemic lupus erythematosus from Sjögren’s syndrome. Arthritis Rheum 43:S303,2000‡.

55. Chen J, Wyatt E, Lee LA, Scofield RH, Farris AD. Autoantibodies to a novel 68 kDkeratinocyte antigen are associated with subacute cutaneous lupus but not with autoantibodies to60 kD Ro antigen. Arthritis Rheum 43:S229, 2000‡

56. Kurien BT, Scofield RH, Harley JB, Bachmann, M. Metal ion mediated protein-proteininteraction of the 60 kD ribonucleoprotein particle. Arthritis Rheum 43:S330S, 2000‡

57. Scofield RH, Thomas PY, Kurien BT. A tertiary epitope with contributions from Ro60 andRo52. Arthritis Rheum 43:S330, 2000‡

58. Scofield RH, Bruner GR, Harley JB. Thrombocytopenia in a large cohort of familial lupus:Evaluation of ethnicity, manifestations and autoantibodies. Lupus 10:S72, 2001. (Presented at theSixth International Lupus Meeting, March 2001)

59. Kurien BT, Scofield RH. Autoantibodies binding Cu-Zn superoxide dismutase and freeradical damage in SLE. Lupus 10:S98, 2001. (Presented at the Sixth International LupusMeeting, March 2001)

60. Kilpatrick J, Kelly J, Scofield RH, Bruner GR, Harley JB. Utilizing clinical data to furtherunderstand the genetics of a complex disease.

61. Kurien BT, Pye QN, Hensley K, Scofield RH. Antibodies to 4-hydroxynonenal-modifiedsuperoxide dismutase monomer and its tetramer in systemic lupus erythematosus. ArthritisRheum 44:S75, 2001‡

62. Scofield RH, Bruner GR, Quintero del Rio AI, Reichlin M, James JA, Harley JB. Familialaggregation of anti-Ro and anti-RNP in families multiplex for lupus. Arthritis Rheum 44:S205,2001‡

63. Scofield RH, Bruner GR, Kelly J, Klein D, Nath SK, James JA, Harley JB.

47

Thrombocytopenia and the genetics of morbidity and mortality in lupus. Arthritis Rheum44:S248, 2001‡

64. Sadanadan P, Aston CE, Quintero del Rio AI, Scofield RH, Aberle T, James JA, Harley JB.Birth order influences the risk of systemic lupus erythematosus. Arthritis Rheum 44:S249, 2001‡

65. Bachmann MP, Kurien BT, Gross JD, James JA, Scofield RH, Harley JB. Does the nuclearautoantigen La/SS-B function by binding/chelating divalent cations. Arthritis Rheum 44:S304,2001‡

66. Bruner GR, Kelly J, Kilpatrick J, Nath SK, Namjou-Khales B, Scofield RH, Harley JB.Hemolytic anemia in pedigrees multiplex for lupus: improving power by increasing genetichomogeneity. Arthritis Rheum 44:S393, 2001‡

67. Kelly JA, Reid J, Kilpatrick J, Harris B, Berry-Brattan CK, Frank S, Hutchings D, JohnsonS, Bacino D, Rossacci K, Aberle T, Namjou B, Nath SK, Bruner GR, Scofield RH, James JA,Harley JB, Cooney C. Combined genome scan results for 266 pedigrees multiplex for systemiclupus erythematosus (SLE): significant evidence of genetic linkage at 1q22-23 and 11p13. Am JFHum Gen 71:1573S, 2002

68. Kelly JA, Thompson K, Kilpatrick J, Lam T, Nath SK, Reid J, Aston CE, Bruner GR,Scofield RH, Harley JB. Evidence for a susceptibility gene (SLEH1) on chromosome 11q14 forsystemic lupus erythematosus families characterized by hemolytic anemia. Clin Immunol.103(Suppl2): S413, 2002

69. Scofield RH, Bruner GR, Kelly JA, Kilpatrick J, Bacino D, Nath SK, Harley JB.Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus andreveals genetic linkages at 1q21 and 11p.13. Clin Immunol.103(Suppl2)3):S446, 2002

70. Kurien BT, Asfa S, Obeso D, Boire G, Scofield RH. Determination of Ro ribonucleoproteinparticle constituents through intermolecular protein-protein interaction of the 60 kD Roautoantigen. Arthritis Rheum 46:S125, 2002‡

71. Kaufman K, Scofield H, Kelly J, Bruner G, Kilpatrick J, Harley JB. Fine mapping ofchromosome 11p13 in African-American SLE families in which SLE is manifested bythrombocytopenia. Arthritis Rheum 46:S288, 2002‡

72. Kurien BT, Ganick S, Obeso D, McClain MT, Pye Q, James JA, Bachmann M, Harley JB,Hensley KM, Scofield RH. 4-hydroxy-2-nonenal modification of 60 kD Ro autantigen increasesantigenicity and facilitates epitope spreading. Arthritis Rheum 46:S450, 2002‡

73. Scofield RH, Farris D, Jonssen R, Kurien B. Immunization of BALB/c mice with 60 kD Ropeptide 480-494, which is a cryptic T cell epitope, induces a Sjögren’s syndrome-like illness.

48

Arthritis Rheum 46:S597, 2002‡

74. Kurien BT, Bachmann M, Scofield RH. Calcium ion makes human recombinant Ro 60 moresoluble and increases its antigenicty in immunoblots. Arthritis Rheum 48:S66, 2003‡

75. Bruner GR, Cooney CM, Aberle T, Scofield RH. Impact of ethnicity of family participationin SLE genetic studies. Arthritis Rheum 48:S250, 2003‡

76. Kurien BT, Asfa S, Dori Y, Li C, Scofield RH. Induction of oral tolerance in anexperimental model of Sjögren’s syndrome. Arthritis Rheum 48:S259, 2003‡

77. Scofield RH, Bruner GR, Harris B, Reid J, Li S, Kelly J, Harley JB. Klinefelter’s syndromeis associated with lupus. Arthritis Rheum 48:S383, 2003‡

78. Chappel CM, Scofield RH, Wallis G, Kurien BT, Morris RI, Centola MB. Distinctmolecular immunopathogenic cytokine profiles of ankylsoing spondylitis. Arthritis Rheum48:S601, 2003‡

79. Scofield RH, Bruner GR, Harris B, Reid J, Sestak A, Li S, Kelly, Harley JB. A Gene DoseHypothesis for the X chromosome in systemic lupus erythematosus: as based upon observationswith 47,XXY; 46,XX; 46,XY; AND 45,XO. J Invest Med 52:S287, 2004 (Presented at the 2004Southern Regional Meetings of the Southern Society for Clinical Investigation and the SouthernDivision of the American Federation for Medical Research, February 13, 2004)

80. Chappell CM, Wallis G, Scofield RH, et al. Distinct immunopathogenic cytokine profiles ofthe spondylarthropathies FASEB J 18 :A190, 2004* 81. Harley JB, Bruner GR, Kelly J, Li S, Scoifeld RH. Evidence from XXY, XX, and XY for agene dose from the X chromosome in human systemic lupus erythematosus FASEB J. 18:A840, 2004*

82. Chappell CM, Wallis G, Osban J, Alex P, Scofield H, Morris R, Metzger A, Dozmorov I,Centola M. Distinct immunopathogenic cytokine profiles of the spondyloarthropathies. ArthritisRheum 50:S210, 2004.‡

83. Namjou B, Bruner G, Scofield RH. Sjögren’s syndrome in associated with autoimmunethyroid disease in systemic lupus families. Arthritis Rheum 50:S576, 2004.‡

84. Kurien BT, Dorri Y, Hensley K, Bachmann M, Scofield RH. Spectrin immunization inducesanti-Ro/anti-La, while Ro60 or 4-hydroxy-2-nonenal-modified Ro60 immunization leads to anti-spectrin. Arthritis Rheum 50:S579, 2004.‡

85. Kurien BT, Asfa S, Li C, Porter AC, D’Sousa A, Scofield RH. Adoptive transfer of

49

lymphocytes from mice with Sjögren’s like syndrome transfers disease into naïve mice. ArthritisRheum 50:S445, 2004.‡

86. D’Sousa A, Koelsch K, Shadfar S, Glenn S, Kelly J, Harley J, Kaufman K, Scofield RH.Towards a genetic ‘association’ between systemic lupus erythematosus and thrombocytopenia.Arthritis Rheum 50:S411, 2004.‡

87. Pham TN, Scofield RH. Glucosamine and insulin resistance. J Invest Med 53:S271, 2005

88. Mosallaei-Benjamin M, Hamadani M, Holla P, Scofield RH, Selby GR. Effects ofhyperglycemia on hematopoietic stem cell transplantation. J Invest Med 53: S322, 2005

89. Iqbal S, Kurien BT, Dorri Y, D'Souza A, Asfa S, Singh A, Matsumoto H, Scofield RH.Salivary protein profile and antibodies to 60 kD Ro and the lipid peroxidation product 4-hydroxy-2-nonenal modified 60 kD Ro in the saliva of an animal model of Sjogren's syndrome.Arthritis Rheum 52:S279, 2005‡

90. Asfa S, Li C, D'Souza A, Dorri Y, Kurien BT, Scofield RH. Induction of salivary glanddysfunction in naive mice by transfer of anti-Ro 274 IgG from mice with Sjogren's likesyndrome. Arthritis Rheum 52:S370, 2005‡

91. Kurien BT, Asfa S, Dorri Y, D'Souza A, Hensley K, Scofield RH. Accelerated induction ofSjogren's syndrome by immunization with 4-hydroxy-2-nonenal modified 60 kD Ro. ArthritisRheum 52:S371, 2005‡

92. Scofield RH. Sjogren's syndrome in SLE families. Arthritis Rheum 52:S375, 2005‡

93. Kurien BT, Iqbal S, Scofield RH. Target sequences modified by the lipid peroxidationproduct 4-hydroxy-2-nonenal in the 60 Kd Ro autoantigen may be part of its tertiary structure. Arthritis Rheum 52:S629, 2005‡

94. Scofield RH, Bruner GR, Harley JB, Namjou B. Autoimmune thyroid disease is associatedwith secondary Sjogren's syndrome in familial systemic lupus. J Invest Med 54:S300-S301,2006§

95. Antalffy K, Rathbun S, Scofield RH, Comp PC, Raskob GE, Esmon CT, Esmon NL.Presence of oxidation dependent activated protein C inhibitory antibodies in deep veinthrombosis. Artherioscler Thromb Vasc Biol 26: E104-E104, 2006

96. D'souza A, Asfa S, Dorri Y, Kurien BT, Scofield RH. Time line of salivary flow dysfunctionand pathology in a Sjogrens syndrome mouse model. Arthritis Rheum 54:S709-S709, 2006‡

97. Dorri Y, Kurien BT, Singh A, Matsumoto H, Scofield RH. Identification of

50

4-hydroxy-2-nonenal modified proteins in the sera of SLE patients: A possible mechanism forinitiating autoimmunity. Arthritis Rheum 54:S462-S462, 2006‡

98. Kurien BT, Fesmire J, Scofield RH Anti-oxidized LDL antibodies cross reacting withanti-phospholipid antibodies in an experimental model of systemic lupus erythematosus. ArthritisRheum 54:S452-S452, 2006‡

99. D'souza A, Kurien BT, Patel NC, Miller DL, Wang H, Scofield RH. Prolidase deficiency insystemic lupus erythematosus. Arthritis Rheum 54:S292-S292, 2006‡

100. Dorri Y, Kurien BT, Singh A, Neufing P, Matsumoto H, Gordon T, Scofield RH.Identification of 4-hydroxy-2-nonenal modified proteins in the sera of Sjogren's syndromepatients using two dimensional gel electrophoresis and mass spectrometry. Arthritis Rheum54:S254-S254, 2006‡

101. Malik S, Bruner GR, Feo L, Williams-Weese C, Scofield RH, Harley JB, Sowalha AH. The presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures inlupus patients. Clin Immunol 123:S81-S82, 2007 (presented at FOCIS 2007, San Diego, CA)

102. Dedecke A, Scofield RH. Omalizumab (xolair) for chronic urticaria. J Invest Med55:S279-S279, 2007§

103. Kandavar R, Prabhu R, Scofield RH Renal failure in hypothyroidism. J Invest Med 55:S262-S262, 2007§

104. Sawalha AH, Webb R, Han S, et al. Genetic association of the X-chromosome geneMECP2 with systemic lupus erythematosus. Arthritis Rheum 58:S219, 2008‡

105. D'souza A, Kurien BT, Scofield RH. Detection of catalase as a major protein target of thelipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE.Arthritis Rheum 58:S811, 2008.‡

106. Thanou A, Zacharias L, Scofield RH, et al. Necrotizing lymphadenitis in a previouslyhealthy young woman: Kikuchi-Fujimoto's disease or systemic lupus erythematosus? J InvestMed 56:362, 2008§

107. Lim J, Mushtaq N, Aggarwal R, et al. Association of body mass index, race/ethnicity andgender in a cohort of systemic lupus erythematosus patients with diabetes and/or hypertension. JInvest Med 56:430, 2008

108. Sawalha AH, Webb R, Han S, Kelly JA, Kaufman KM, Kimberly RP, Alarcon-RiquelmeME, James JA, Vyse TJ, Gilkeson GS, Choi CB, Scofield RH, Bae SC, Nath SK, Harley JB.Genetic association of the X-chromosome gene MECP2 with systemic lupus erythematosus

51

Arthritis Rheum 58:S219, 2008‡

109. D'souza A, Kurien BT, Scofield RH Detection of catalase as a major protein target of thelipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLEArthritis Rheum 58:S811-S812, 2008‡

110. Thanou A, Zacharias L, Scofield RH, Staudt L. Necrotizing lymphadenitis in a previouslyhealthy young woman: Kikuchi-Fujimoto's disease or systemic lupus erythematosus? J Invest Med 56:362, 2008§

111. Lim J, Mushtaq N, Aggarwal R, Scofield RH. Association of body mass index,race/ethnicity and gender in a cohort of systemic lupus erythematosus patients with diabetesand/or hypertension. J Invest Med 56:430, 2008§ 112. Scofield RH, Scofield AK. Peripheral neuropathy in Sjogren’s syndrome. J Invest Med58:442, 2010§

113. Hendrickson CD, D'Souza A, Ritterhouse LL, Moser KL, Scofield RH. 25-OH-Vitamin Dlevels in patients with Sjogren’s syndrome and systemic lupus erythematosus J Invest Med 58:470, 2010§

114. Aggarwal R, Scofield RH. Fewer male siblings and increased male fetal loss in a cohort ofsystemic lupus erythematosus. J Invest Med 58:471, 2010§

115. Lessard CJ, Ice JA, Adrianto I, et al. A High-Density Genome-Wide Association Study bythe Sjogren's Genetics Network Identifies Five Novel Susceptibility Loci for Primary Sjogren'sSyndrome and Confirms Association with MHC, IRF5, and BLK. Arthritis Rheum 63:S184,2011‡

116. Kelly JA, Lessard CJ, Adrianto I, et al. Gene Expression Profiling in a Cohort of 275European American Sjogren's Syndrome Patients and Controls. Arthritis Rheum 63:S187, 2011‡

117. Deng Y, Zhao J, Tan W, et al. Association of a Functional Variant in TLR7 with SystemicLupus Erythematosus and Rheumatoid Arthritis in Multiple Ancestries. Arthritis Rheum63:S246, 2011‡

118. Ramos PS, Oates JC, Kamen DL, et al. Association of Reactive Intermediate Genes withSystemic Lupus Erythematosus (SLE) Varies Across Populations with Different African Ancestries. Arthritis Rheum 63:S250, 2011‡

119. Dillon SP, Kao, Kaufman KM, et al. Triple X Syndrome (47,XXX) Increases the Risk andAccelerates the Onset of Systemic Lupus Erythematosus and Sjogren's Syndrome: Support for aGene-Dose Effect From the X Chromosome. Arthritis Rheum 63:S251, 2011‡

52

120. Lessard CJ, Adrianto I, Ice JA, et al. Large-Scale, High-Density Genotyping Performed bythe Sjogren's Genetics Network Using the ImmunoChip Identifies PRKRA as a Novel Sjogren'sSyndrome Susceptibility Locus and Confirms Associations with IRF5, BLK and MHC. ArthritisRheum 63:S303-304, 2011‡

121. Hughes Travis, Adler A, Merrill JT, et al. Sex-Specific Genetic Architecture of SystemicLupus Erythematosus. Arthritis Rheum 63:S57, 2011‡ 122. Lim J, Mushtaq N, Aggarwal R, et al. Association of Body Mass Index, Race/Ethnicity andGender in a Cohort of Systemic Lupus Erythematosus Patients with Diabetes and/orHypertension. Arthritis Rheum 63:S723, 2011‡

123. Deng Y, Zhao J, Sakurai D, et al. The SLE-Associated TLR7 Variant Confers DifferentialGene Expression Modulated by MicroRNA-3148. Arthritis Rheum 64:S689, 2012‡

124. Edberg JC, Duarte CW, Patki A, et al. Genetic Interactions Between SNP Variants in C3Receptor Sub-units in Patients with SLE. Arthritis Rheum 64:S420, 2012‡

125. Giles BM, Zhao J, Lough K, et al. Preferential Association of Complement Receptor 2Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus. Arthritis Rheum64:S965, 2012‡

126. Ice JA, Li H, Kelly JA, et al. Use of Global Gene Expression Profiling to CharacterizeSjogren's Patients Who Underexpress Interferon-Inducible Genes. Arthritis Rheum 64:S228,2012‡

127. Kurien BT, D'souza A, Dillon SP, et al. Prolidase Deficiency Induces Antibodies to Sm,Ro60 and Double Stranded DNA. Arthritis Rheum 64:S289, 2012‡

128. Kurien BT, Fesmire J, Dillon SP, et al. Antibodies to Oxidized Low Density Lipoprotein orAnti-Lipoprotein Lipase May Lead to More Atherosclerotic Plaque in a Sub-Set of SLE Patients.Arthritis Rheum 64:S291, 2012‡

129. Lessard CJ, Li H, Adrianto I, et al. A Genome-Wide Association Study Establishes MulipleSusceptibility Loci for Sjogren's Syndrome. Arthritis Rheum 64:S1133, 2012‡

130. Li H, Ice JA, Kelly JA, et al. Gene Expression Profiling in a Large Cohort of Europeanswith Sjogren's Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-RelatedPathways. Arthritis Rheum 64:S229, 2012‡

131. Li H, Ice JA, Kelly JA, et al. Cis-Expression Quantitative Trait Loci Analysis ofDysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates forSusceptibility to Sjogren's Syndrome. Arthritis Rheum 64:S1134, 2012‡

53

132. Rasmussen A, Ice JA, Li H, et al. Effects of Reclassification Using the American Collegeof Rheumatology Criteria On a Large cohort Sjogren's Syndrome Patients. Arthritis Rheum64:S931, 2012‡

133. Adrianto I, Dozmorov MG, Wiley GB. RNA-Sequencing Identifies Novel DifferentiallyExpressed Coding and Non-Coding Transcripts In Sjogren's Syndrome. Arthritis Rheum65:S632, 2013‡

134. Altorok NI, Coit PS, Hughes T, et al. Genome-Wide DNA Methylation Patterns In naiveCD4+T Cells From Patients With Primary Sjogren's Syndrome. Arthritis Rheum 65:S1186,2013‡

135. Dumancas G, Brown M, Adrianto I, et al. A Novel Screening Tool Indicative Of PrimarySjogren's Syndrome Versus Sicca Symptoms. Arthritis Rheum 65:S224, 2013‡

136. Grewa S, James JA, Scofield RH, et al. Vitamin D In Sjogren's Syndrome. Arthritis Rheum65:S227, 2013‡

137. Harris V, Kurien BT, Scofield RH, et al. Antibodies To Anti-Type-3 MuscarinicAcetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With4-Hydroxy-2-Noneal-Modified and 60-Kda Ro. Arthritis Rheum 65:S636, 2013‡

138. Igoe A, Lessard CJ, Anaya, J-M, et al. Sjogren's Syndrome In American Ethnic and RacialMinorities. Arthritis Rheum 65:S221, 2013‡

139. Koristka S, Cartellier M, Arndt C, et al. Bispecific Antibodies For Redirection Of HumanRegulatory T Cells To Surface-Inducible Autoantigen La/SS-B. Arthritis Rheum 65:S696,2013‡

140. Lessard CJ, Li H, Adrianto I, et al. Complex Functional Effects Within The HLAContribute To Sjogren's Syndrome Pathogenesis and May Influence Both TranscriptionalRegulation and Peptide Binding. Arthritis Rheum 65:S1184, 2013‡

141. Li H, Ice JA, Kelly JA, et al. Identification Of a Sjogren's Syndrome-Associated VariantThat Influences OAS1 Isoform Switching. Arthritis Rheum 65:S1186, 2013‡

142. Liu K, Kaufman KM, James JA, ... Scofield RH. Sex Bias In Autoimmune Diseases:Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjogren's Syndrome(SS) Supports The Gene Dose Hypothesis. Arthritis Rheum 65:S379, 2013‡

143. Michalk I, Berndt, N, Bippes CC, et al. Redox Dependent Conformational Changes Of TheAutoantigen La Are Responsible For Its Shuttling, Translocation and a Pathophysiological RoleOf Anti-La Autoantibodies. Arthritis Rheum 65:S396, 2013‡

54

144. Ice JA, Adrianto I, Li H, Rasmussen A, Wiley GB, Stone DU, Segal BM, Rhodus NL,Radfar L, James JA, Montgomery CG, Scofield RH, Gaffney PM, Thompson LF, Farris AD,Kovats S, Wren A, Sivils KL, Lessard CJ. Characerization of a Sjögren’s syndrome-associatednon-conding RNA at 2p25.1, An Rheum Dis, in press (presented at the European League AgainstRheumatism annual scientific meeting, Rome, Italy, June 2015

145. Scofield RH, Igoe A, Stone DU, Radfar L, Hefner KS, Lewis DM, Young S, Harris J,Grundahl K, Kurien BT. Anti-Ro/SSA Positive Incomplete Sjogren's Syndrome. Arthritis Rheum66:S1111-S1112, 2014‡

146. Rasmussen A, Brown M, Stone DU, Earley K, Hefner KS, Radfar L, Lewis DM, Young S,Rhodus NL, Segal BM, Lessard CJ, Montgomery CG, Scofield RH, Sivils KL. Performance ofthe Ocular Staining Score (OSS) Vs. the Van Bijsterveld Score in the Assessment of Sjogren'sSyndrome-Related Keratoconjunctivitis Sicca. Arthritis Rheum 66:S1108-S1109, 2014‡

147. Leehan KM, Brown M, Montgomery C, Rasmussen A, Lewis DM, Radfar L, Stone DU,Young S, Scofield RH, Sivils KLM, Farris, AD. Precisely Quantified Fibrosis in Labial SalivaryGlands Predicts Sjogren's Syndrome Classification in a Multiple Regression Model. ArthritisRheum 66:S1280-S1280, 2014‡

148. Koelsch KA, Maier-Moore J, Smith K, Lessard C, Rasmussen A, Kurien B, Deshmukh U,Farris AD, James JA, Sivils KLM, Scofield RH, Coggeshall M. Labial Salivary GlandAntibody-Secreting Cell Specificity and Characteristics in Sjogren's Patients. Athritis Rheum66:S438-S439, 2014‡

149. Kaplonek P, Szczerba B, Wolska N, Rybakowska P, Klopocki A, Dey P, Rasmussen A,Hefner K, Young S, Stone DU, Lewis DM, Radfar L, Scofield RH, Sivils KM, Bagavant H,Deshmukh U. Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for theInduction of Sjogren's Syndrome-like Disease in Mice. Arthritis Rheum 66:S790-S790, 2014‡

150. Ice JA, Li H, Adrianto I, Dozmorov MG, Rasmussen A, Wiley GB, Kelly JA, Hefner KS,Stone DU, Gopalakrishnan R, Lewis DM, Young S, Rohrer MD, Anaya JM, Venuturupalli S,Segal BM, Rhodus NL, Radfar L, Weisman MH, James JA, Montgomery CG, Scofield RH,Gaffney PM, Thompson LF, Farris AD, Kovats S, Wren JD, Sivils KL, Lessard CJ. Characterization of the Sjogren's Syndrome Intergenic Non-Coding RNA 1 (SSINCR1).Arthritis Rheum 66: S1302-S1302, 2014‡

151. Danda D, Truong D, Shaw M, Quang C, Koelsch KA, Kurien BT, Bagavant H, DeshmukhU, Scofield RH. La Positive, Ro60 Negative Subset of Primary Sjogren's Syndrome Is a Reality.Arthritis Rheum 66: S1111-S1111, 2014‡

152. Rasmussen A, Grundahl K, Radfar L, Lewis D, Stone D, Kaufman E, Wallace D,Weisman M, Venuturapalli S, Kurien BT, Lessard CJ, Sivils KL, Scofield, RH. Previous

55

Diagnosis of Sjogren's Syndrome as Rheumatoid Arthritis or Systemic Lupus ErythematosusScand J Immunol 81:332, 2015 May (presented at the 15th International Sjögren’s Symposium,Bergen, Norway, 19-22 May 2015)

153. Rasmussen A, Brown M, Earley K, Hefner K, Radfar L, Lewis D, Young S, Kaufman CE,Segal B, Lessard CJ, Montgomery C, Scofield RH, Stone D, Sivils KL. Performance of theOcular Staining Score (OSS) vs. the van Bijsterveld Score in the Assessment of Sjogren'sSyndrome-Related Keratoconjunctivitis Sicca. Scand J Immunol 81:335, 2015 May (presentedat the 15th International Sjögren’s Symposium, Bergen, Norway, 19-22 May 2015)

154. Rasmussen A, Kelly JA, Ice J, Li H, Wiley G, Stone D, Kaufman E, Radfar L, Lewis D,Young SK, Weisman M, Venuturupalli S, Segal B, Lessard CJ, Scofield RH, Sivils KL.Characterization of Early and Progressive Autoimmunity in Sjogren's Syndrome: The IncompleteSjogren's Syndrome Model. Scand J Immunol 81:341, 2015 May (presented at the 15th

International Sjögren’s Symposium, Bergen, Norway, 19-22 May 2015) 155. Stone DU, Earley K, Rasmussen A, Chodosh J, Gopalakrishnan R, Grundahl K, Hefner K,Houston G, Huang A, Kaufman CE, Lessard C, Lewis D, Montgomery C, Radfar L, Rhodus N,Rohrer M, Scofield RH, Segal B, Siatkowski R, Sivils K. Effect of Punctal Occlusion andTopical Cyclosporine on the Diagnosis of Sjogren's Syndrome. Scand J Immunol 81:342, 2015May (presented at the 15th International Sjögren’s Symposium, Bergen, Norway, 19-22 May2015)

156. Carsons S, Parke A, Segal B, Carteron N, Sankar V, Brasington R, Fox RI, Ehlers W,Brennan M, Scofield RH, Hurley P, Hammitt K, Vivino F. Sjogren's Syndrome Foundation(SSF) Clinical Practice Guidelines for Systemic Management: Treatment of InflammatoryMusculoskeletal (MSK) Pain, Fatigue and Use of Biologics. Scand J Immunol 81:375, 2015May (presented at the 15th International Sjögren’s Symposium, Bergen, Norway, 19-22 May2015)

157. Joachims ML, Leehan KM, Lawrence CL, Rasmussen A, Scofield RH, Sivils KL,Thompson LF, Farris AD. Expansions of Salivary Gland CD4(+) T Cells from Sjogren'sSyndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures ofDisease. Scand J Immunol 81:384, 2015 May (presented at the 15th International Sjögren’sSymposium, Bergen, Norway, 19-22 May 2015)

158. Scofield RH. Recombinant Monoclonal Antibodies Derived from Salivary GlandInfiltrating Antibody Secreting Cells. Scand J Immunol 81:394, 2015 May (presented at the15th International Sjögren’s Symposium, Bergen, Norway, 19-22 May 2015)

159. Danda D, Truong D, Shaw M, Quang C, Koelsch K, Kurien BT, Bagavant H, Deshmukh U,Scofield RH. Ro Negative, La Positive Subset of Primary Sjogren's Syndrome is a Reality.Scand J Immunol 81:395, 2015 May (presented at the 15th International Sjögren’s Symposium,

56

Bergen, Norway, 19-22 May 2015)

160. Harris V, Girton M, Kurien B, Scofield RH. Inhibitory Antibodies to Type-3 MuscarinicAcetylcholine Receptor (M3R) are Highly Prevalent in Rabbits Immunized with 60-kDa Ro.Scand J Immunol 81:400, 2015 May (presented at the 15th International Sjögren’s Symposium,Bergen, Norway, 19-22 May 2015)

161. Koelsch KA, Quadri SMS, Harris VM, Kurien BT, Deshmukh US, Rasmussen A, SivilsKL, Farris AD, Scofield RH. Single-Cell Production and Characterization of Fully-HumanMonoclonal Antibodies from the Minor Salivary Glands of Sjogren's Patients. Scand J Immunol81:401, 2015 May (presented at the 15th International Sjögren’s Symposium, Bergen, Norway,19-22 May 2015)

162. Harris VM, Liu K, Cavett J, Kurien BT, Alarcon-Riquelme ME, Harley JB, Sivils KL,Weisman MH, Rasmussen A, Scofield RH. X Chromosome Aneuploidies in Sjogren'sSyndrome: Comparison to Systemic Lupus and Rheumatoid Arthritis. Scand J Immunol 81:417,2015 May (presented at the 15th International Sjögren’s Symposium, Bergen, Norway, 19-22 May2015)

163. Kurien BT, Harris V, Quadri SMS, Cavett J, Moyer A, Ittiq B, Metcalf A, Koelsch K,Centola M, Payne A, deSouza, PC, Danda D, Scofield, RH. Ultrasoluble Curcumin/TurmericAmeliorates Lesions and Increases Survival in a Mouse Model of Sjogren's Syndrome andLupus. Scand J Immunol 81:424, 2015 May (presented at the 15th International Sjögren’sSymposium, Bergen, Norway, 19-22 May 2015)

164. Stone DU, Rasmussen A, Earley K, Grundahl K, Radfar L, Hefner K, Rohrer M,Gopalakrishnan R, Houston G, Lewis D, Chodosh J, Siatkowski R, Kaufman CE, Huang A,Young S, Rhodus N, Segal B, Scofield RH, Montgomery C, Lessard C, Sivils, K. TobaccoSmoking and Sjogren's Syndrome. Scand J Immunol 81:442, 2015 May (presented at the 15th

International Sjögren’s Symposium, Bergen, Norway, 19-22 May 2015)

165. Harris VM, Kurien BT, Liu K, Harley JB, Scofield. The triple X chromosome mosaic,45,X/46,XX/47,XXX, among women with systemic lupus erythematosus. Clin Exp Rheumatol33(Suppl 90):S-61, 2015 (Sep) (Presented at the 11th International Congress on Systemic LupusErythematosus, Vienna, Austria, 2-6 September 2015).

166. Kurein BT, Harris VM, Quadri SMS, De Souza PC, Cavett J, Moyer A, Ittiq B, Metcalf A,Ramji HF, Truong D, Koelsch KA, Centola, M, Payne A, Danda D, Scofield RH. Clin ExpRheumatol 33(Suppl 90):S-34, 2015 (Sep) (Presented at the 11th International Congress onSystemic Lupus Erythematosus, Vienna, Austria, 2-6 September 2015).

167. Harley, IT W, Vaughn S, Williams AH, et al. Association of CLEC16A with SLE in aLarge Multi-Ancestry Cohort and Implication in B-Cell Receptor Signaling. Arthritis

57

Rheumatol 67:1869, 2015 Oct ‡

168. Harris VM, Cavett J. Kurien BT, et al. Klinefelter's Syndrome (47,XXY) Among Men withSjogren's Syndrome. Arthritis Rheumatol 67:648, 2015 Oct‡ 169. Joachims ML, Leehan KM, Lawrence CM, et al. Expansions of Salivary Gland CD4+TCells from Sjogren's Syndrome Patients: Single-Cell Repertoire Analysis and Correlation withClinical Measures of Disease. Arthritis Rheumatol 67:1055, 2015 Oct‡

170. Kurien BT, Harris VM, Quadri, SMS, et al. Significantly Reduced Lymphadenopathy,Salivary Gland Infiltrates and Proteinuria in MRL-Lpr/Lpr Mice Treated with UltrasolubleCurcumin/Turmeric: Increased Survival with Curcumin Treatment. Arthritis Rheumatol67:1776, 2015 Oct‡

171. Lessard CJ, Li H, Ice J, et al. Identification of Novel Sjogren's Syndrome Risk Loci in theRegions of TNFAIP3 and PRDM1. Arthritis Rheumatol 67:1052, 2015 Oct‡

172. Quadri SMS, Koelsch KA, Harris V, et al. Functional Anti-Muscarinic Receptor-3Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjogren's Syndrome.Arthritis Rheumatol 67:3202, 2015 Oct‡

173. Rasmussen A, Lessard CJ, Adrianto I, et al. Characterization of Early and ProgressiveAutoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model. ArthritisRheumatol 67:3202, 2015 Oct‡

174. Rasmussen A, Radfar, L, Grundahl K, et al. Previous Diagnosis of Sjogren's Syndrome AsRheumatoid Arthritis or Systemic Lupus Erythematosus. Arthritis Rheumatol 67:621, 2015Oct‡

175. Sharma R, Rasmussen A, Radfar L, et al. Ethnicity of Sjogren's Syndrome. ArthritisRheumatol 67:643, 2015 Oct‡

176. Vivino FB, Carsons SE, Parke Ann, et al. Sjogren's Syndrome Foundation Clinical PracticeGuidelines for Management of Systemic Disease. Arthritis Rheumatol 67:625, 2015 Oct‡

177. Wolska N, Rybakowska P, Klopocki A, et al. Co-Occurence of Anti-Ro52/TRIM21 andAnti-TRIM38 Autoantibodies Is Associated with Higher Severity of Dry Eye in Sjogren'sSyndrome. . Arthritis Rheumatol 67:2802, 2015 Oct‡

† Presented at the American Federation of Clinical Research/American Society of ClinicalInvestigation/American Association of Physicians national meeting* Presented at the American Association of Immunologist national meeting‡ Presented at the American College of Rheumatology national scientific meeting

58

§ Presented at the Southern Society of Clinical Investigation Annual meeting

Other Media

“American Indian Living - Arthritis,” Hosted by David DeRose, MD, produced by Life TalkRadio in Tennessee, November 23, 2004 (Also broadcast delayed on many public radio stationsin Indian Country via American Indian Radio on Satellite a division of Native American PublicTelecommunication.

“Glucosamine, diabetes and insulin resistance,” The Health Report, hosted by Norman Swan,MD, Australian Broadcast Network National Radio, September 17, 2007

Invited Presentations

Local/Regional

"Wernicke's Encephalopathy", University of Oklahoma Health Sciences Center Medical GrandRounds, April 1988.

"The Incidentally Found Cerebral Aneurysm", University of Oklahoma Health Sciences CenterMedical Department of Medicine Mortality and Morbidity, April 1988.

"Tularemia in Oklahoma", University of Oklahoma Health Sciences Center Medical GrandRounds, September 1988.

"The 'New' Euthyroid Sick Syndrome", University of Oklahoma Health Sciences Center MedicalGrand Rounds, August 1989.

"Hypoglycemia in an Elderly Woman", University of Oklahoma Health Sciences CenterDepartment of Medicine Mortality and Morbidity Conference, August 1989.

"Myxedema Coma", University of Oklahoma Health Sciences Center Department of MedicineClinical Care Conference, May 1991.

"Therapy of Hypertension", Oklahoma Filipino Medical Society, September, 1991.

"Vesicular Stomatitis Virus - An Etiologic Theory of Systemic Lupus Erythematosus",University of Oklahoma Health Sciences Center Department of Pathology Research Conference,September, 1991.

"Steroid Abuse by Athletes and Others", University of Oklahoma Health Sciences Center

59

Medical Grand Rounds, September, 1991.

"Metabolic Problems in the Critically Ill", University of Oklahoma Health Sciences CenterAnnual Critical Care Course, March 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997.

"Molecular Mimicry as an Etiology of Autoimmune Disease", OUHSC, The Science Forum,November 7, 1991.

"An Update on Clinical and Basic Science Research Concerning Type II Diabetes Mellitus",Indian Health Service Prevention and Detection of Complications in Type II Diabetes,November, 1992.

"Hyperparathyroidism - An Update", University of Oklahoma Health Sciences Center MedicalGrand Rounds, November, 1992.

"Steroid Abuse", HCA Presbyterian Hospital Internal Medicine Grand Rounds, Oklahoma City,OK, July 1993

"Polyglandular Autoimmunity: Oklahoma and Beyond", University of Oklahoma HealthSciences Center Medical Grand Rounds, September, 1993

"Drugs and Athletic Performance", Oklahoma City University Drug Awareness Program,October, 1993

"Hypercalcemia while on CAPD - Tertiary hyperparathyroidism", University of OklahomaHealth Sciences Center Department of Medicine Clinical Care Conference, January, 1994

"Diagnostic Approach to Thyroid Nodules", University of Oklahoma Health Sciences CenterSurgery Grand Rounds, May, 1994

"The Medical Consequences of the Voyage of Columbus", University of Oklahoma HealthSciences Center Medical Grand Rounds, February, 1995.

"The Immunology of Systemic Lupus Erythematosus", Southwestern Oklahoma University,March 1995

"Research and the Clinician", Department of Medicine, University of Oklahoma Health SciencesCenter Intern and Resident Research Day, May 1995.

"The medical legacy of the discovery of the New World", University of Oklahoma HealthSciences Center, The Science Forum, June 22 and 29, 1995.

"Diarrhea and Cushing's syndrome", University of Oklahoma Health Sciences Center Department

60

of Medicine Clinical Care Conference, August, 1995

"Hyperviscosity in a patient without plasma cell dyscrasia", University of Oklahoma HealthSciences Center Medical Grand Rounds, February, 1996.

"The genetics of spondyloarthropathy," The Science Forum, University of Oklahoma HealthSciences Center, March 20, 1997

"Rheumatic Illnesses in American Indians," University of Oklahoma Health Sciences CenterMedical Grand Rounds, October, 1997

"Hyperparathyroidism Update," Oklahoma Chapter of the American College ofPhysicians/Oklahoma Society of Internal Medicine Annual Meeting, Norman, OK, November,1997

"Latex Allergy," University of Oklahoma Health Sciences Center, The Science Forum,December, 1997

"Medical Outcomes of the Voyage of Columbus," Classen School for Advanced Studies,Oklahoma City, OK, September 22, 1998

"Mortality, cardiovascular disease and lipids in systemic lupus erythematosus," University ofOklahoma Health Sciences Center Medical Grand Rounds, January 6, 1999.

"Lipid Peroxidation and anti-SOD in Systemic Lupus," Free Radical & Aging Program Seminar,Oklahoma Medical Research Foundation, February 21, 2000

"Evidence-Based Treatment of Osteoporosis," University Health Partners Pharmacy Conference,University of Oklahoma Health Sciences Center, March 2, 2000

"Diagnostic Approach to Hypoglycemia," University of Oklahoma Health Sciences CenterMedical Grand Rounds, March 15, 2000.

"Update in Thyroid Disease," Primary Care Update, University of Oklahoma Health SciencesCenter, June 2000

“Serendipity in science and the genetics of lupus,” The Science Forum, University of OklahomaHealth Science Center, December 7, 2000

“Hypoglycemia - Diabetes and beyond,” Primary Care Update, University of Oklahoma HealthScience Center Continuing Medical Education Office, Lawton, OK, February 17, 2001

“Latex Allergy,” 48 th Annual James F. Hammarsten Pulmonary Conference - Oklahoma Lung

61

Association Annual Meeting, Oklahoma City, OK, May 5, 2001

“Management of cardiovascular risk in diabetes,” 4th Annual Diabetes Update, University ofOklahoma Health Sciences Center, Oklahoma City, OK, May 5, 2001

“Integrating the New Diabetes Therapies,” Oklahoma Academy of Family Practice ContinuingEducation, Tulsa, OK, January 8, 2002, repeated in OKC, Lawton, Ardmore, Muskogee, PoncaCity (3/03), Tulsa (4/29/03), Bartlesville (4/29/03).

“Anti-TNF therapy in rheumatoid arthritis,” Pottawatomie County Medical Society, Shawnee,Oklahoma, February 19, 2002.

“Hypertension and lipid treatment in diabetes,” 72nd Medical Group Grand Rounds, Tinker AirForce Base Hospital, Oklahoma City, OK,March 25, 2002

“Use of the newer NSAIDs in acute pain,” Oklahoma Podiatric Medicine Association AnnualMeeting, Oklahoma City, OK, May 3, 2002

“The New Genetics of Lupus,” Oklahoma-Arkansas Bistate Society of Clinical LaboratoryScientists Meeting, May 7, 2002, Oklahoma City, OK

“Care of diabetes in the hospital,” University of Oklahoma Health Sciences Center MedicalGrand Rounds, June 19, 2002

“Informed Consent: Current Issues and Solutions - Surrogate Consent,” Human ResearchProtections: Current Issues and Solutions, Office for Human Research Protections and Universityof Oklahoma Health Sciences Center, Oklahoma City, OK, September 18-20, 2002

“Care of diabetes in the hospital,” Oklahoma American College of Physicians/American Societyof Internal Medicine Annual Meeting, Tulsa, Oklahoma, September 20, 2002

“Hypercalcemia crisis with hypervitaminosis D,” University of Oklahoma Health SciencesCenter, Department of Medicine Morbidity and Mortality Conference, March 14, 2003.

“Hypo-and hyperglycemic emergencies,” Certified Diabetes Educator Conference, University ofOklahoma Health Sciences Center, April, 2003

“New insulin strategies in the treatment of diabetes,’ Oklahoma Academy of Family PracticeChoice CME, Bartlesville, OK - April 29, 2003, Oklahoma City - Mar 29, 2003, Tulsa - Sept 7,2003.

“Tight control of blood sugar in the hospital - the most important advance in critical care since

62

the ventilator,” Oklahoma Academy of Family Physicians Annual meeting, Tulsa, OK, June 21,2003.

“Update on rheumatoid arthritis,” Oklahoma Chapter of the American College of PhysiciansAnnual Meeting, Oklahoma City, OK, September 13, 2003

“Update on rheumatoid arthritis,” Payne County Medical Society CME, Stillwater MedicalCenter Monthly CME, Stillwater, OK, September 23, 2003

“What’s new in diabetes research,” 2nd Annual Oklahoma’s Solutions for Diabetes: Building aCommunity of Practice, November 14, 2003

“Diabetes in the hospital,” Family Medicine Grand Rounds, University of Oklahoma HealthSciences Center, Oklahoma City, OK, December 10, 2003

“Autoantibodies predicting disease,” Pediatric Grand Rounds, University of Oklahoma HealthSciences Center, December 18, 2003

“Autoantibodies predicting disease,’ Payne County Medical Society CME, Stillwater MedicalCenter, Stillwater, OK, January 20, 2004

“Diabetes Mellitus - Efficacy, tolerance and compliance,” Oklahoma Academy of FamilyPractice Choice CME, Tulsa, January 24, 2004, Oklahoma City, January 31, 2004

“New strategies for Type 2 diabetes,” 72nd Medical Group Grand Rounds, Tinker Air Force Base,Oklahoma City, OK, February 11, 2004

“DKA, NKHOS and hypoglycemia,” Payne County Medical Society CME, August 24, 2004

“Rheumatoid arthritis and the medical consequences of Columbus,” Oklahoma State HealthDepartment Arthritis Prevention Program, November 11, 2004, Oklahoma City, OK

“Update on regulatory actions concerning COX2 inhibitors,” Altus, Oklahoma, April 28, 2005

“What’s new in Sjögren’s research,” Oklahoma Sjögren’s Foundation Annual meeting, MercyHospital, Oklahoma City, OK, April 30, 2005

“Fibromyalgia,” University of Oklahoma Health Science Center Primary Care Update, May 18,2005, Oklahoma City

“Autoantibodies as Predictors of disease,” Oklahoma Academy of Family Physicians ScientificAssembly, June 18, 2005, Tulsa, OK

63

“Insulin in type 2 diabetes,” Oklahoma Academy of Family Physicians Scientific Assembly, June18, 2005, Tulsa, OK

“New Developments in NSAIDs - FDA actions and cardiovascular disease,” April 28, 2005,Altus, OK; August 9, 2005, McAlester, OK; September 27, 2005, Ponca City, OK;

“The X in Sex: Biology and pathobiology of the X Chromosome. Medical Grand Rounds,University of Oklahoma Health Sciences Center, June 28, 2005

“Care of Diabetes in the Hosptial,” Mercy Hospital Grand Rounds, Ardmore, OK, August 25,2005

“Update on fibromylagia,” Integris Baptist Medical Center Internal Medicine Staff Meeting,October 10, 2005, Oklahoma City, OK

“Lupus among men,” Lupus Foundation of America, Oklahoma Chapter, September 16, 2006

“Update on medical therapy,” Sjögren’s Syndrome Foundation, Oklahoma Chapter, November 5,2006

“Endocrine approach to hirsutism,” OUHSC Department of Dermatology Grand Rounds, January4, 2007

“Hyperglycemic Emergencies,” Payne County Medical Society, Stillwater, Oklahoma, March 27,2007.

“Hyertension in Diabetes,” OUHSC Diabetes Educators Update, May 1, 2007

“Encretin Hormones in Diabetes,” OUHSC Diabetes Educators Update, May 1, 2007

“Diabetes Update,” OUHSC 10th Annual Primary Care Update, May 29, 2007

“Update on hospitalized diabetes care - What’s wrong with DIGAMI 2", Medicine GrandRounds, Department of Medicine, OUHSC, July 25, 2007

“Metabolic Syndrome,” OUHSC 11th Annual Primary Care Update, May 14, 2008, OklahomaCity, OK

“Diabetes Cardiovascular Health Issues,” Oklahoma Academy of Family Physicians AnnualMeeting, June 14, 2008, Oklahoma City, OK

“Arthritis and Chronic Pain,” Oklahoma Academy of Family Physicians Annual Meeting, June14, 2008, Oklahoma City, OK

64

“Diabetes and Diabetes Genetics,” Genetics counseling students, OUHSC, November 18, 2008

“Sex chromosomes and SLE,” Internal Medicine Grand Rounds, OUHSC, December 10, 2008.

“CTSA initiative in Oklahoma,” Cardiovascular Grand Rounds, OUHSC, January 6, 2009

“Metabolic Syndrome - What’s new,” Norman Regional Hospital Staff Meeting CME, March17th, 2009

“Epidemiology, diagnosis, genetics and treatment of diabetes,” American Studies ProgramGraduate Class, Department of Anthropology, University of Oklahoma, Norman, OK, March24th, 2009

“Type 2 diabetes in Oklahoma - diagnosis and prevention,” American Diabetes AssociationMedia Day, Chesapeake Boat House, Oklahoma City, OK, March 25th, 2009

“Sjögren’s syndrome - Update on clinical and research aspects,” Otolaryngology Grand Rounds,OUHSC, March 25th, 2009

“Preventive care in patients with diabetes,” Internal Medicine Monthly Seminar, NormanRegional Hospital, Norman, Oklahoma, March 31st, 2009.

“Lupus and Sjögren’s,” Autoimmune disease symposium, McAlaster Hospital, McAlaster,Oklahoma, May 1-2, 2009.

“Sleep Apnea and Diabetes,” Diabetes Management and Teaching Strategies 2009: Beyond theBasics, Tulsa Oklahoma, May 5-6, 2009.

“Molecular Biology: A primer for Clinicians,” Mercy Hospital Internal Medicine Grand Rounds,Oklahoma City, OK, August 12, 2009.

“The Henry Turner Lecture - Sex Chromosome Aneuploidies in Autoimmune Disease”, OUHSC,Oklahoma City, OK, February 9, 2011

“Evidence based medicine: A personal perspective in the information age”, Annual Evidence-Based Medicine Workshop, OUHSC, September 9, 2011

“Refractory Hypertension,” Oklahoma City Department of Veterans Affairs Medical CenterPrimary Care Conference, Oklahoma City, OK, January 11, 2012.

“Sex, toxins and autoimmunity”, Functional Medicine Association of North Texas, Forest ParkMedical Center, Dallas, Texas, April 14, 2012

65

“Sjögren’s syndrome and the GI tract”, Sjögren’s syndrome Support Group, Edmond, Oklahoma,3 November 2012.

“Endocrinology Pearls for Rheumatologists”, William K. Ishmael Lectureship, Oklahoma City,Oklahoma, 1 March 2013

“The History of Self-Experimentation,” Graduate Student Forum, Oklahoma Medical ResearchFoundation, 10 April 2013

“The Biology and Sociology of Creativity,” Graduate Student Forum, Oklahoma ResearchFoundation, 8 January 2014.

“Metabolic Syndrome - An Update”, OUHSC 17th Annual Primary Care Update, 13 May 2014

National/International

"Spondyloarthropathies, bacterial peptides and HLA-B27," Department of Immunology, MayoClinic and Foundation, April, 1996.

"Short peptide immunization induces lupus humoral autoimmunity and systemic disease," NewYork Academy of Sciences Conference - B Lymphocytes and Autoimmunity, Prague, The CzechRepublic, May, 1996.

Visiting Professor, Pathophysiology, Univerisidad de Guadalajara Autónoma, Guadalajara,Mexico, January 1997.

"Non-HLA-B27 alleles in spondyloarthropathy," Spondyloarthropathy Study Group, AmericanCollege of Rheumatology National Scientific Meeting, Washington, DC, November, 1997.

"Anti-Ro in Clinical and Experimental SLE," Forum of Immunobiology, Center of MolecularBiology, Universidad Autónoma de Madrid, Madrid, Spain, February 16, 1998

"Anti-Ro and antibodies to white blood cells," Fourth International Neonatal Lupus CollaboratorsMeeting, Milan, Italy, May, 1998.

"Induced and naturally arising Anti-Ro," Catalan Society of Immunology, Barcelona, Spain, June25, 1998

"Thyroid Disease and Sjögren's Syndrome," Ninth Annual National Conference for Sjögren'sSyndrome by the National Sjögren's Syndrome Association, October 31, 1998

"Peptide immunization induced lupus autoimmunity: 60 kD Ro/SSA peptides with different

66

outcomes," Keystone Conference: Immunogenetics of human disease - MHC/TCR and peptide,Taos, New Mexico, January 18, 1999.

"Human and experimental anti-Ro immunity," Broegelmann Research Laboratory, Department ofMicrobiology and Immunology, University of Bergen, Bergen, Norway, July 2, 1999

"60 kD Ro immunization induces lupus autoimmunity," Arthritis Research Conference,sponsored by the Arthritis Foundation, NIAMS and NIAID, Alexandria, Virginia, August, 1999

"Genetics of human and animal lupus," Accelerated Atherosclerosis in SLE, sponsored byNIAMS and NHLBI, Chevy Chase, MD, September 8-9, 1999

"Medical Aspects of Rheumatic Disease - Hyperlipidemia," American College of RheumatologyNational Scientific Meeting, Boston, MA, November, 1999

"A New Hypothesis for the Pathogenesis of Spondyloarthropathy," Rheumatology ResearchConference, State University of New York - Downstate, Brooklyn, New York, February 15, 2000

"Atherosclerosis and lipids in Systemic Lupus Erythematosus," Medical Grands Rounds, StateUniversity of New York - Downstate, Brooklyn, New York, February 17, 2000

"Hu-SCID Mice in the Study of Systemic Lupus erythematosus," Chiron Inc Life Science Center,Oakland, California, August 22, 2000.

“Immune Response to the HLA-B27 Heavy Chain in humans,” Spondyloarthropathy BasicScience Symposium, American College of Rheumatology National Meeting, Philadelphia, PA,November 2000

“Autoantibodies binding Cu-Zn superoxide dismutase and free radical damage in SLE,” SixthInternational Lupus Conference, Barcelona, Spain, March 28, 2001

“Genetics of a Severe Lupus Phenotype,” Lupus Genetics - An International Conference,Oklahoma Medical Research Foundation, September 9, 2001

“Back-to-Basics: A fresh approach to musculosleletal problems - Use of COX-2 selectiveNSAIDs,” Joplin, Missouri, April 13, 2002

“Induction of anti-Ro and anti-La by Immunization,” 6th Dresden Symposium on Autoantibodiesand Autoantigens, Dresden, Germany, September 2002.

“Sjögren’s Syndrome,” Workshop on Autoantibodies as Predictors of Autoimmune Diseases,National Institutes of Health (NIAMS and NIAID), September 12-13, 2002.

67

“What causes lupus - a theoretical discussion,” 7 th International Lupus Congress, New York,New York, May 11, 2004

“Autoantibodies are predictors of disease: Present status and future research,” Department ofMedicine Research Seminar, University of Missouri School of Medicine, Columbia, Missouri,July 7, 2004.

“A theoretical discussion on the causes of lupus,” Third Annual Lupus Educational Symposium,Sponsored by UT Southwestern Medical School, North Texas Chapter of the Lupus Foundationand Texas Scottish Rite Hospital, Dallas, Texas, October 30, 2004

“Autoantibodies predicting disease,” at CELLIAD symposium - Curative Therapies in RheumaticDiseases, Berlin, Germany, June 20-21, 2005

“Roundtable on Gender and Sex Factors in inflammation,” National Institute of Health, January31, 2007

“Data Sharing and the Bioethics of Collaborative Genetic Research Conference,” NationalInstitute of Allergy and Infectious Disease – Bioinformatics Integration and Support Contract,Dallas, Texas, January 17-18, 2007

“Autoantibodies as predictors of disease,” Southern Society for Clinical Research Annualmeeting, New Orleans, February 9, 2007

“Free Radical Damage in Autoimmune Disease,” Henry Kunkel Society Annual Meeting, NewYork, New York, April 27, 2007

“The sex chromosomes in SLE,” Second International Lupus Genetics Conference, OklahomaCity, Oklahoma, October, 2008.

“Animal Models of Sjögren’s syndrome,” Sjögren’s Working Group, American College ofRheumatology National meeting, San Francisco, CA, October 25, 2008

“When men have two X chromsomes: Klinefelter’s and Autoimmunity,” Organization for theStudy of Sex Differences in Disease Annual meeting, Toronto, Canada, June 4-6, 2009.

“Mentored Discussion: Sjögren’s syndrome and Vitamin D”, Southern Regional Meetings,February 27, 2010, New Orleans, LA

“Autoimmunity in Klinefelter’s Syndrome,” International Workshop on Klinefelter’s Syndrome,Copenhagen, Denmark, May 6-8, 2010.

Chair, “Could Tolerance to Self Antigens be Broken by Immune Responses to Modified

68

Autoantigens” at Role of Beta Cell Antigen Modifications in the Pathogenesis of Type 1Diabetesand their Diagnostic and Therapeutic Potential, Juvenile Diabetes Research Foundation, NewYork, December 13, 2010.

“The X Chromosome in Rheumatic Diseases,” Center for Autoimmunity Genetics and Etiology,University of Cincinnati School of Medicine and Cincinnati Children’s Hospital, Cincinnati,Ohio, August 24, 2011

“Sex chromosome aneuploidies explain the sex-bias in Sjögren’s syndrome.” XI InternationalSjögren’s Congress, Athens, Greece, September, 2011.

“Sex Chromosome Aneuploidies in Lupus and Sjögren’s Syndrome,” Indian RheumatologyAssociation Annual Scientific Congress, Vellore, India, December 5-8, 2011

“Sex Chromosome Aneuploidies explain the sex bias of Lupus and Sjögren’s,” Organization forthe Study of Sex Differences in Disease annual scientific meeting, Wehawken, New Jersey, April26, 2013

“A new mechanism for pathogenesis in Sjögren’s”, Sjögren’s Syndrome Study Section,American College of Rheumatology National Scientific Meeting, San Diego, CA, October 2013

“Rheumatic manifestation of endocrine disease”, LupusConnect, national teleconference for theIndian Health Service, 14 January 2014

“Free Radical Damage in lupus”, Oxygen Radicals Gordon Research Conference, Ventura,California, 9-14 February 2014

“Pathogenesis of Sjögren’s Syndrome,” Asian and Pacific League Against Rheumatism Scientificmeeting, Cebu City, Philippines, 1-4 April 2014

“Sex Differences in Microbiome”, Microbiome and Autoimmune Disease Colloquium: A NoelR. Rose Colloquium on Autoimmunity, Leesburg, VA, 16-18 May 2014. “Sex Differences in Genetics of Rheumatic Diseases”, AAOS/CORR/ORS/CMH-UCD/SWHR Musculoskeletal Sex Differences Throughout the Lifespan Research Symposium, July 30-August 1, 2014, Rosemont, Illinois

“Research Opportunities in Sjögren’s Syndrome”, Autoimmune Summit, Lilly Corporation,September 9, 2014, Indianapolis, Indiana

“Human recombinant monoclonal antibodies from Sjögren’s syndrome”, 15th InternationalSjögren’s Symposium, Bergen, Norway, May 2015

69

“Managing exocrine and endocrine autoimmunity”, New York University Langone Seminar inAdvanced Rheumatology, New York City, March 19-20, 2016

“Rare X aneuploidies in Lupus and Sjögren’s”, Lupus Research Alliance Annual ScientificConference, New York City, October 24-25, 2016

“Diagnosis and Mis-Diagnosis of Sjögren’s Syndrome”, Keynote Lecture, Six Provences ofSouth-Central China Annual Symposium, Changsha, Hunan, China, October 28-29, 2016

“The sex bias of lupus and Sjögren’s - Cecil Martin Distinguished Lecture”, Southern IllinoisCollege of Medicine, Springfield, Illinois, November 1, 2016.

70

71